STUDYID,DOMAIN,USUBJID,AESEQ,AESPID,AETERM,AELLT,AELLTCD,AEDECOD,AEPTCD,AEHLT,AEHLTCD,AEHLGT,AEHLGTCD,AEBODSYS,AEBDSYCD,AESOC,AESOCCD,AESER,AEACN,AEACNOTH,AEREL,AERELNST,AEOUT,AESCONG,AESDISAB,AESDTH,AESHOSP,AESLIFE,AESMIE,AECONTRT,AETOXGR,ETCD,ELEMENT,EPOCH,AESTDTC,AEENDTC,AESTDY,AEENDY,AEENRTPT,AEENTPT
0200066003,AE,     1,1.0,11,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-11,2013-07-11,3.0,3.0,,
0200066003,AE,     1,2.0,17,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,2013-11-26,68.0,141.0,,
0200066003,AE,     1,3.0,6,,Anxiety,10002855.0,Anxiety,10002855.0,Anxiety symptoms,10002869.0,Anxiety disorders and symptoms,10002861.0,Psychiatric disorders,10037175.0,Psychiatric disorders,10037175.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-13,2013-08-14,36.0,37.0,,
0200066003,AE,     1,4.0,7,,Anxiety,10002855.0,Anxiety,10002855.0,Anxiety symptoms,10002869.0,Anxiety disorders and symptoms,10002861.0,Psychiatric disorders,10037175.0,Psychiatric disorders,10037175.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-20,******,43.0,,AFTER,STUDY END
0200066003,AE,     1,5.0,18,,Dehydration,10012174.0,Dehydration,10012174.0,Total fluid volume decreased,10044084.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,2013-09-25,68.0,79.0,,
0200066003,AE,     1,6.0,21,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,NOT APPLICABLE,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2013-09-20,2013-09-25,74.0,79.0,,
0200066003,AE,     1,7.0,20,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,UNRELATED,NONE,,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,2013-09-19,68.0,73.0,,
0200066003,AE,     1,8.0,19,,Device failure,10056871.0,Device failure,10056871.0,Device issues NEC,10069794.0,Device issues,10069782.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-11,2013-09-11,65.0,65.0,,
0200066003,AE,     1,9.0,10,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-11,2013-07-11,3.0,3.0,,
0200066003,AE,     1,10.0,2,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,SCRN,Screening,SCREENING,2013-07-03,2013-07-15,-6.0,7.0,,
0200066003,AE,     1,11.0,3,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-16,2013-07-29,8.0,21.0,,
0200066003,AE,     1,12.0,4,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-30,2013-12-30,22.0,175.0,,
0200066003,AE,     1,13.0,12,,Sensation of heat,10039999.0,Feeling hot,10016334.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-09,2013-08-27,1.0,50.0,,
0200066003,AE,     1,14.0,8,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-16,2013-07-16,8.0,8.0,,
0200066003,AE,     1,15.0,16,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,******,68.0,,AFTER,STUDY END
0200066003,AE,     1,16.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-23,2013-07-30,15.0,22.0,,
0200066003,AE,     1,17.0,24,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2013-09-20,2013-09-25,74.0,79.0,,
0200066003,AE,     1,18.0,9,,Red face,10038190.0,Erythema,10015150.0,Erythemas,10015151.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-09,2013-07-09,1.0,1.0,,
0200066003,AE,     1,19.0,13,,General physical health deterioration,10049438.0,General physical health deterioration,10049438.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,2013-11-12,68.0,127.0,,
0200066003,AE,     1,20.0,5,,Sleep disorder,10040984.0,Sleep disorder,10040984.0,Sleep disorders NEC,10040993.0,Sleep disorders and disturbances,10040991.0,Psychiatric disorders,10037175.0,Psychiatric disorders,10037175.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-11,2013-08-14,34.0,37.0,,
0200066003,AE,     1,21.0,22,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-09-14,2013-09-19,68.0,73.0,,
0200066003,AE,     1,22.0,23,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,,3,PTP,Post Treatment Period,POST TREATMENT,2013-09-20,2013-09-25,74.0,79.0,,
0200066003,AE,     2,1.0,2,,Normochromic normocytic anaemia,10029783.0,Normochromic normocytic anaemia,10029783.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,DRUG INTERRUPTED,,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-23,2013-11-26,28.0,31.0,,
0200066003,AE,     2,2.0,3,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG WITHDRAWN,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,Y,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-24,******,29.0,,AFTER,STUDY END
0200066003,AE,     2,3.0,4,,Liver failure,10024678.0,Hepatic failure,10019663.0,Hepatic failure and associated disorders,10019664.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-12-01,2013-12-20,36.0,55.0,,
0200066003,AE,     2,4.0,5,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-18,2013-11-21,23.0,26.0,,
0200066003,AE,     2,5.0,1,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DOSE NOT CHANGED,NONE,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-18,2013-11-21,23.0,26.0,,
0200066003,AE,     3,1.0,6,,Ascites,10003445.0,Ascites,10003445.0,Peritoneal and retroperitoneal disorders,10034653.0,Peritoneal and retroperitoneal conditions,10034652.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2015-01-10,******,451.0,,AFTER,STUDY END
0200066003,AE,     3,2.0,1,,Hypochromic anemia,10020971.0,Hypochromic anaemia,10020969.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-02,******,78.0,,AFTER,STUDY END
0200066003,AE,     3,3.0,5,,Oedema legs,10030105.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2015-01-10,******,451.0,,AFTER,STUDY END
0200066003,AE,     3,4.0,2,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-23,2014-01-23,99.0,99.0,,
0200066003,AE,     3,5.0,3,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-13,2014-02-13,120.0,120.0,,
0200066003,AE,     3,6.0,4,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-03-19,154.0,154.0,,
0200066003,AE,     4,1.0,1,,Reduced general condition,10057364.0,General physical health deterioration,10049438.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,NONE,FATAL,,,Y,,,,,3,SCRN,Screening,SCREENING,2013-07-11,2013-07-22,,,,
0200066003,AE,     5,1.0,28,,Alanine aminotransferase increased,10001551.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-16,2013-12-23,100.0,198.0,,
0200066003,AE,     5,2.0,12,,Alanine aminotransferase increased,10001551.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-08,2013-09-02,30.0,86.0,,
0200066003,AE,     5,3.0,19,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-11,2013-12-09,64.0,184.0,,
0200066003,AE,     5,4.0,3,,ALT increased,10001845.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-16,2013-06-22,8.0,14.0,,
0200066003,AE,     5,5.0,100,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-08,2015-01-12,548.0,583.0,,
0200066003,AE,     5,6.0,104,,Ascites,10003445.0,Ascites,10003445.0,Peritoneal and retroperitoneal disorders,10034653.0,Peritoneal and retroperitoneal conditions,10034652.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-15,******,555.0,,AFTER,STUDY END
0200066003,AE,     5,7.0,21,,Asiderotic anemia,10064648.0,Iron deficiency anaemia,10022972.0,Anaemia deficiencies,10002042.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-22,2013-09-29,44.0,113.0,,
0200066003,AE,     5,8.0,17,,Aspartate aminotransferase increased,10003481.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-11,2013-08-26,64.0,79.0,,
0200066003,AE,     5,9.0,27,,Aspartate aminotransferase increased,10003481.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-16,2013-10-28,100.0,142.0,,
0200066003,AE,     5,10.0,41,,Aspartate aminotransferase increased,10003481.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-02,2013-12-09,177.0,184.0,,
0200066003,AE,     5,11.0,31,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-10-06,114.0,120.0,,
0200066003,AE,     5,12.0,32,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-07,2013-10-14,121.0,128.0,,
0200066003,AE,     5,13.0,33,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-11-11,135.0,156.0,,
0200066003,AE,     5,14.0,40,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-18,2013-12-02,163.0,177.0,,
0200066003,AE,     5,15.0,18,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-11,2013-08-18,64.0,71.0,,
0200066003,AE,     5,16.0,20,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-19,2013-08-25,72.0,78.0,,
0200066003,AE,     5,17.0,22,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-26,2013-10-20,79.0,134.0,,
0200066003,AE,     5,18.0,34,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-11-17,135.0,162.0,,
0200066003,AE,     5,19.0,44,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-19,2014-01-06,194.0,212.0,,
0200066003,AE,     5,20.0,2,,Hyperbilirubinemia,10020582.0,Hyperbilirubinaemia,10020578.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-16,2013-06-29,8.0,21.0,,
0200066003,AE,     5,21.0,8,,Hyperbilirubinemia,10020582.0,Hyperbilirubinaemia,10020578.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-07-14,22.0,36.0,,
0200066003,AE,     5,22.0,43,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-02,2013-12-09,177.0,184.0,,
0200066003,AE,     5,23.0,82,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-06,2014-10-13,485.0,492.0,,
0200066003,AE,     5,24.0,29,,Hypochromic anemia,10020971.0,Hypochromic anaemia,10020969.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-11-04,114.0,149.0,,
0200066003,AE,     5,25.0,67,,ALT increased,10001845.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-25,2014-05-31,351.0,357.0,,
0200066003,AE,     5,26.0,94,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-24,******,534.0,,AFTER,STUDY END
0200066003,AE,     5,27.0,86,,ALT increased,10001845.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-27,2014-11-10,506.0,520.0,,
0200066003,AE,     5,28.0,93,,LDH increased,10024051.0,Blood lactate dehydrogenase increased,10005630.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-24,2014-12-01,534.0,541.0,,
0200066003,AE,     5,29.0,103,,LDH increased,10024051.0,Blood lactate dehydrogenase increased,10005630.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-15,2014-12-22,555.0,562.0,,
0200066003,AE,     5,30.0,4,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-16,2013-06-22,8.0,14.0,,
0200066003,AE,     5,31.0,6,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-23,2013-06-29,15.0,21.0,,
0200066003,AE,     5,32.0,7,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-07-28,22.0,50.0,,
0200066003,AE,     5,33.0,16,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-19,2013-09-02,72.0,86.0,,
0200066003,AE,     5,34.0,24,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-23,2013-09-29,107.0,113.0,,
0200066003,AE,     5,35.0,30,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-10-20,114.0,134.0,,
0200066003,AE,     5,36.0,35,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-10-28,135.0,142.0,,
0200066003,AE,     5,37.0,46,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-06,2014-01-20,212.0,226.0,,
0200066003,AE,     5,38.0,49,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-03,2014-03-16,268.0,281.0,,
0200066003,AE,     5,39.0,50,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-17,2014-03-30,282.0,295.0,,
0200066003,AE,     5,40.0,51,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-31,2014-04-07,296.0,303.0,,
0200066003,AE,     5,41.0,59,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-28,2014-05-12,324.0,338.0,,
0200066003,AE,     5,42.0,66,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-16,2014-07-06,373.0,393.0,,
0200066003,AE,     5,43.0,68,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-14,2014-07-21,401.0,408.0,,
0200066003,AE,     5,44.0,73,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-18,2014-09-14,436.0,463.0,,
0200066003,AE,     5,45.0,75,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-15,2014-09-21,464.0,470.0,,
0200066003,AE,     5,46.0,78,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-22,2014-09-29,471.0,478.0,,
0200066003,AE,     5,47.0,81,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-06,2014-10-12,485.0,491.0,,
0200066003,AE,     5,48.0,85,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-13,2014-10-20,492.0,499.0,,
0200066003,AE,     5,49.0,89,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-10,2014-11-16,520.0,526.0,,
0200066003,AE,     5,50.0,90,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-17,2014-11-24,527.0,534.0,,
0200066003,AE,     5,51.0,95,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-01,2014-12-07,541.0,547.0,,
0200066003,AE,     5,52.0,97,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-08,2014-12-14,548.0,554.0,,
0200066003,AE,     5,53.0,102,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-15,2015-01-04,555.0,575.0,,
0200066003,AE,     5,54.0,105,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-01-05,2015-01-11,576.0,582.0,,
0200066003,AE,     5,55.0,108,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-01-12,2015-02-02,583.0,604.0,,
0200066003,AE,     5,56.0,5,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-23,2013-06-29,15.0,21.0,,
0200066003,AE,     5,57.0,11,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-07-21,22.0,43.0,,
0200066003,AE,     5,58.0,14,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-22,2013-07-28,44.0,50.0,,
0200066003,AE,     5,59.0,23,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-19,2013-09-02,72.0,86.0,,
0200066003,AE,     5,60.0,25,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-23,2013-10-07,107.0,121.0,,
0200066003,AE,     5,61.0,36,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-10-28,135.0,142.0,,
0200066003,AE,     5,62.0,47,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-27,2014-01-20,202.0,226.0,,
0200066003,AE,     5,63.0,54,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-03,2014-03-16,268.0,281.0,,
0200066003,AE,     5,64.0,55,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-17,2014-03-24,282.0,289.0,,
0200066003,AE,     5,65.0,56,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-31,2014-04-07,296.0,303.0,,
0200066003,AE,     5,66.0,69,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-14,2014-07-21,401.0,408.0,,
0200066003,AE,     5,67.0,76,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-15,2014-09-21,464.0,470.0,,
0200066003,AE,     5,68.0,79,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-22,2014-09-29,471.0,478.0,,
0200066003,AE,     5,69.0,92,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-17,2014-11-24,527.0,534.0,,
0200066003,AE,     5,70.0,101,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-08,2014-12-22,548.0,562.0,,
0200066003,AE,     5,71.0,109,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-01-05,2015-01-19,576.0,590.0,,
0200066003,AE,     5,72.0,13,,Serous retinal detachment,10040114.0,Retinal detachment,10038848.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,NOT APPLICABLE,NONE,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-06,2013-09-23,28.0,107.0,,
0200066003,AE,     5,73.0,71,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-11,2014-08-17,429.0,435.0,,
0200066003,AE,     5,74.0,88,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-10,2014-11-16,520.0,526.0,,
0200066003,AE,     5,75.0,1,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-16,2013-06-22,8.0,14.0,,
0200066003,AE,     5,76.0,9,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-23,2013-06-29,15.0,21.0,,
0200066003,AE,     5,77.0,10,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-08-04,22.0,57.0,,
0200066003,AE,     5,78.0,15,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-19,2013-09-09,72.0,93.0,,
0200066003,AE,     5,79.0,26,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-23,2013-10-07,107.0,121.0,,
0200066003,AE,     5,80.0,37,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-14,2013-10-20,128.0,134.0,,
0200066003,AE,     5,81.0,38,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-10-28,135.0,142.0,,
0200066003,AE,     5,82.0,39,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-11,2013-11-25,156.0,170.0,,
0200066003,AE,     5,83.0,42,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-09,2013-12-23,184.0,198.0,,
0200066003,AE,     5,84.0,45,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-06,2014-01-20,212.0,226.0,,
0200066003,AE,     5,85.0,48,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-03,2014-02-24,240.0,261.0,,
0200066003,AE,     5,86.0,52,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-03,2014-03-09,268.0,274.0,,
0200066003,AE,     5,87.0,53,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-10,2014-04-27,275.0,323.0,,
0200066003,AE,     5,88.0,57,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-28,2014-05-04,324.0,330.0,,
0200066003,AE,     5,89.0,58,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-05,2014-05-12,331.0,338.0,,
0200066003,AE,     5,90.0,60,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-19,2014-05-24,345.0,350.0,,
0200066003,AE,     5,91.0,61,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-25,2014-05-31,351.0,357.0,,
0200066003,AE,     5,92.0,62,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-01,2014-06-09,358.0,366.0,,
0200066003,AE,     5,93.0,63,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-16,2014-06-22,373.0,379.0,,
0200066003,AE,     5,94.0,64,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-23,2014-06-29,380.0,386.0,,
0200066003,AE,     5,95.0,65,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-30,2014-07-06,387.0,393.0,,
0200066003,AE,     5,96.0,70,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-14,2014-08-10,401.0,428.0,,
0200066003,AE,     5,97.0,72,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-18,2014-09-14,436.0,463.0,,
0200066003,AE,     5,98.0,74,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-15,2014-09-21,464.0,470.0,,
0200066003,AE,     5,99.0,77,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-09-22,2014-09-29,471.0,478.0,,
0200066003,AE,     5,100.0,80,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-06,2014-10-12,485.0,491.0,,
0200066003,AE,     5,101.0,83,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-13,2014-10-19,492.0,498.0,,
0200066003,AE,     5,102.0,84,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-10-20,2014-10-27,499.0,506.0,,
0200066003,AE,     5,103.0,87,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-03,2014-11-09,513.0,519.0,,
0200066003,AE,     5,104.0,91,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-11-17,2014-12-07,527.0,547.0,,
0200066003,AE,     5,105.0,98,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-08,2014-12-14,548.0,554.0,,
0200066003,AE,     5,106.0,99,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-12-15,2015-01-05,555.0,576.0,,
0200066003,AE,     5,107.0,106,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-01-05,2015-01-11,576.0,582.0,,
0200066003,AE,     5,108.0,107,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-01-12,2015-01-19,583.0,590.0,,
0200066003,AE,     5,109.0,110,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2015-02-02,******,604.0,,AFTER,STUDY END
0200066003,AE,     6,1.0,2,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,MULTIPLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-03,2013-08-14,8.0,19.0,,
0200066003,AE,     6,2.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-03,2013-08-14,8.0,19.0,,
0200066003,AE,     7,1.0,6,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-09,2013-09-09,43.0,43.0,,
0200066003,AE,     7,2.0,14,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-10-28,85.0,92.0,,
0200066003,AE,     7,3.0,18,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-23,2013-12-30,148.0,155.0,,
0200066003,AE,     7,4.0,23,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-20,2014-02-11,176.0,198.0,,
0200066003,AE,     7,5.0,13,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-10-21,64.0,85.0,,
0200066003,AE,     7,6.0,5,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-09,2013-09-30,43.0,64.0,,
0200066003,AE,     7,7.0,22,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-23,2014-01-13,148.0,169.0,,
0200066003,AE,     7,8.0,25,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-20,2014-02-11,176.0,198.0,,
0200066003,AE,     7,9.0,33,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-28,******,215.0,,AFTER,STUDY END
0200066003,AE,     7,10.0,2,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-26,2013-09-02,29.0,36.0,,
0200066003,AE,     7,11.0,4,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-02,2013-09-09,36.0,43.0,,
0200066003,AE,     7,12.0,7,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-09,2013-09-25,43.0,59.0,,
0200066003,AE,     7,13.0,15,,Low platelets,10024922.0,Platelet count decreased,10035528.0,Platelet analyses,10035523.0,Haematology investigations (incl blood groups),10018851.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-11,2013-11-18,106.0,113.0,,
0200066003,AE,     7,14.0,3,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-02,2013-09-23,36.0,57.0,,
0200066003,AE,     7,15.0,11,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-07,2013-10-14,71.0,78.0,,
0200066003,AE,     7,16.0,12,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-14,2013-10-21,78.0,85.0,,
0200066003,AE,     7,17.0,16,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-18,2013-12-02,113.0,127.0,,
0200066003,AE,     7,18.0,17,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-09,2013-12-16,134.0,141.0,,
0200066003,AE,     7,19.0,19,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,,,,,,,Y,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-23,2013-12-30,148.0,155.0,,
0200066003,AE,     7,20.0,20,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2014-01-05,155.0,161.0,,
0200066003,AE,     7,21.0,27,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-06,2014-01-13,162.0,169.0,,
0200066003,AE,     7,22.0,24,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-20,2014-02-11,176.0,198.0,,
0200066003,AE,     7,23.0,35,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-21,2014-02-27,208.0,214.0,,
0200066003,AE,     7,24.0,29,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,MULTIPLE,,RELATED,NONE,,,,,,,Y,Y,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-28,2014-03-07,215.0,222.0,,
0200066003,AE,     7,25.0,30,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-03-07,2014-03-14,222.0,229.0,,
0200066003,AE,     7,26.0,8,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-12,2013-08-12,15.0,15.0,,
0200066003,AE,     7,27.0,9,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-15,2013-08-15,18.0,18.0,,
0200066003,AE,     7,28.0,10,,Pleural effusion,10035598.0,Pleural effusion,10035598.0,Pneumothorax and pleural effusions NEC,10035761.0,Pleural disorders,10035597.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,NOT APPLICABLE,,UNRELATED,NONE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-20,2013-09-20,54.0,54.0,,
0200066003,AE,     7,29.0,26,,Pleural effusion,10035598.0,Pleural effusion,10035598.0,Pneumothorax and pleural effusions NEC,10035761.0,Pleural disorders,10035597.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-26,******,182.0,,AFTER,STUDY END
0200066003,AE,     7,30.0,36,,Serous detachment of the macula,10062968.0,Macular detachment,10075873.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-18,******,205.0,,AFTER,STUDY END
0200066003,AE,     7,31.0,34,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-21,2014-03-06,208.0,221.0,,
0200066003,AE,     7,32.0,31,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,Y,MULTIPLE,NONE,RELATED,NONE,,,,,,,Y,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-03-07,2014-03-13,222.0,228.0,,
0200066003,AE,     7,33.0,32,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-03-14,******,229.0,,AFTER,STUDY END
0200066003,AE,     7,34.0,21,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-23,2013-12-30,148.0,155.0,,
0200066003,AE,     8,1.0,17,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-19,2013-11-28,244.0,253.0,,
0200066003,AE,     8,2.0,14,,Aerophagia,10052813.0,Aerophagia,10052813.0,"Flatulence, bloating and distension",10016770.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-31,2013-11-06,225.0,231.0,,
0200066003,AE,     8,3.0,5,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,2,SCRN,Screening,SCREENING,2013-03,2013-03,,,,
0200066003,AE,     8,4.0,4,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-16,2013-04-16,27.0,27.0,,
0200066003,AE,     8,5.0,12,,Hemorrhage of digestive tract,10055270.0,Gastrointestinal haemorrhage,10017955.0,Non-site specific gastrointestinal haemorrhages,10017958.0,Gastrointestinal haemorrhages NEC,10017959.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DRUG WITHDRAWN,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-10,2014-01-22,296.0,308.0,,
0200066003,AE,     8,6.0,8,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-19,2013-05-19,60.0,60.0,,
0200066003,AE,     8,7.0,16,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-12,2013-11-14,237.0,239.0,,
0200066003,AE,     8,8.0,21,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-10,2014-01-13,296.0,299.0,,
0200066003,AE,     8,9.0,13,,Hypoglycemia,10021005.0,Hypoglycaemia,10020993.0,Hypoglycaemic conditions NEC,10021001.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-31,2013-10-31,225.0,225.0,,
0200066003,AE,     8,10.0,7,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-08,******,80.0,,AFTER,STUDY END
0200066003,AE,     8,11.0,1,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-21,2013-04-25,1.0,36.0,,
0200066003,AE,     8,12.0,18,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-26,2013-11-26,251.0,251.0,,
0200066003,AE,     8,13.0,20,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-11,2014-01-22,297.0,308.0,,
0200066003,AE,     8,14.0,3,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-03,2013-04-10,14.0,21.0,,
0200066003,AE,     8,15.0,10,,Tooth pain,10059723.0,Toothache,10044055.0,Dental pain and sensation disorders,10044049.0,Dental and gingival conditions,10044018.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-11,2013-09-20,175.0,184.0,,
0200066003,AE,     8,16.0,2,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-22,2013-03-22,2.0,2.0,,
0200066003,AE,     8,17.0,9,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-19,2013-05-19,60.0,60.0,,
0200066003,AE,     8,18.0,15,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-12,2013-11-14,237.0,239.0,,
0200066003,AE,     8,19.0,11,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-27,2014-01-13,282.0,299.0,,
0200066003,AE,     9,1.0,6,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-26,2013-08-29,41.0,44.0,,
0200066003,AE,     9,2.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-31,2013-08-07,15.0,22.0,,
0200066003,AE,     9,3.0,3,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-28,2013-09-04,43.0,50.0,,
0200066003,AE,     9,4.0,7,,Viral infection,10047461.0,Viral infection,10047461.0,Viral infections NEC,10047465.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DRUG INTERRUPTED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-26,2013-08-28,41.0,43.0,,
0200066003,AE,    10,1.0,4,,ALT increased,10001845.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-24,2013-05-29,10.0,15.0,,
0200066003,AE,    10,2.0,3,,AST increased,10003544.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-24,2013-05-29,10.0,15.0,,
0200066003,AE,    10,3.0,5,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-05-25,2013-06-12,11.0,29.0,,
0200066003,AE,    10,4.0,12,,Biliary tract infection,10061695.0,Biliary tract infection,10061695.0,Hepatobiliary and spleen infections,10064462.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,Y,NOT APPLICABLE,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,Y,,,Y,4,PTP,Post Treatment Period,POST TREATMENT,2013-06-04,2013-06-06,21.0,23.0,,
0200066003,AE,    10,5.0,11,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,NOT APPLICABLE,NONE,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,Y,,,,4,PTP,Post Treatment Period,POST TREATMENT,2013-06-04,******,21.0,,AFTER,STUDY END
0200066003,AE,    10,6.0,6,,Cough,10011224.0,Cough,10011224.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-18,2013-05-29,4.0,15.0,,
0200066003,AE,    10,7.0,1,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-19,2013-05-29,5.0,15.0,,
0200066003,AE,    10,8.0,9,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-06-02,2013-06-06,19.0,23.0,,
0200066003,AE,    10,9.0,8,,Hypochondrial pain,10020964.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-06-01,2013-06-12,18.0,29.0,,
0200066003,AE,    10,10.0,10,,Jaundice,10023126.0,Jaundice,10023126.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-05-27,2013-06-12,13.0,29.0,,
0200066003,AE,    10,11.0,13,,Malaise,10025482.0,Malaise,10025482.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,,UNRELATED,OTHER,FATAL,,,Y,,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2013-06-04,2013-06-12,21.0,29.0,,
0200066003,AE,    10,12.0,7,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-19,2013-05-21,5.0,7.0,,
0200066003,AE,    10,13.0,2,,Bilirubin total increased,10056806.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-24,2013-06-04,10.0,21.0,,
0200066003,AE,    11,1.0,2,,Ascites,10003445.0,Ascites,10003445.0,Peritoneal and retroperitoneal disorders,10034653.0,Peritoneal and retroperitoneal conditions,10034652.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DRUG INTERRUPTED,LED TO STUDY TERMINATION,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,Y,,,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-28,******,198.0,,AFTER,STUDY END
0200066003,AE,    11,2.0,5,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2014-04-02,2014-04-02,231.0,231.0,,
0200066003,AE,    11,3.0,1,,Body temperature increased,10005911.0,Body temperature increased,10005911.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-19,2013-12-29,127.0,137.0,,
0200066003,AE,    11,4.0,6,,Epigastric pain,10015026.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-28,2014-03-14,198.0,212.0,,
0200066003,AE,    11,5.0,3,,Weakness generalized,10047865.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,Y,,,,3,MPTP,Monotherapy Post Treatment Period,MONOTHERAPY POST TREATMENT,2014-03-21,******,219.0,,AFTER,STUDY END
0200066003,AE,    11,6.0,7,,Hypoalbuminaemia,10020942.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,MPTP,Monotherapy Post Treatment Period,MONOTHERAPY POST TREATMENT,2014-03-19,******,217.0,,AFTER,STUDY END
0200066003,AE,    11,7.0,9,,Hypocalcemia,10020949.0,Hypocalcaemia,10020947.0,Calcium metabolism disorders,10006975.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-02-27,******,197.0,,AFTER,STUDY END
0200066003,AE,    12,1.0,12,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-28,2013-11-14,107.0,154.0,,
0200066003,AE,    12,2.0,8,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-31,2013-09-26,79.0,105.0,,
0200066003,AE,    12,3.0,11,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-27,2013-11-14,106.0,154.0,,
0200066003,AE,    12,4.0,5,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-12,2013-07-17,29.0,34.0,,
0200066003,AE,    12,5.0,6,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-18,2013-09-30,35.0,109.0,,
0200066003,AE,    12,6.0,15,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-01,2013-11-14,110.0,154.0,,
0200066003,AE,    12,7.0,2,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-24,2013-06-24,11.0,11.0,,
0200066003,AE,    12,8.0,4,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-12,2013-09-26,29.0,105.0,,
0200066003,AE,    12,9.0,14,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-27,2013-11-14,106.0,154.0,,
0200066003,AE,    12,10.0,7,,Flu syndrome,10016793.0,Influenza,10022000.0,Influenza viral infections,10022005.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-25,2013-08-26,73.0,74.0,,
0200066003,AE,    12,11.0,9,,Flu syndrome,10016793.0,Influenza,10022000.0,Influenza viral infections,10022005.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-07,2013-09-09,86.0,88.0,,
0200066003,AE,    12,12.0,10,,Flu syndrome,10016793.0,Influenza,10022000.0,Influenza viral infections,10022005.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-15,2013-09-16,94.0,95.0,,
0200066003,AE,    12,13.0,16,,Obstructive jaundice,10029982.0,Jaundice cholestatic,10023129.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,Y,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2013-10-10,2013-10-27,119.0,136.0,,
0200066003,AE,    12,14.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-20,2013-07-04,7.0,21.0,,
0200066003,AE,    12,15.0,13,,Weight loss,10047900.0,Weight decreased,10047895.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-20,2013-11-14,99.0,154.0,,
0200066003,AE,    13,1.0,3,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,1,SCRN,Screening,SCREENING,2013-09-02,2013-09-26,-5.0,20.0,,
0200066003,AE,    13,2.0,5,,Cardiac disorder,10061024.0,Cardiac disorder,10061024.0,Cardiac disorders NEC,10007543.0,Cardiac disorder signs and symptoms,10007539.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-09-27,2013-09-27,21.0,21.0,,
0200066003,AE,    13,3.0,4,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-09-27,2013-09-27,21.0,21.0,,
0200066003,AE,    13,4.0,2,,Urinary infection,10046544.0,Urinary tract infection,10046571.0,Urinary tract infections,10046577.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,Y,MULTIPLE,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-08,2013-09-20,2.0,14.0,,
0200066003,AE,    14,1.0,9,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,SCRN,Screening,SCREENING,2013-03-19,******,-6.0,,AFTER,STUDY END
0200066003,AE,    14,2.0,2,,Rash,10037844.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-31,2013-04-22,7.0,29.0,,
0200066003,AE,    14,3.0,5,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,******,1.0,,AFTER,STUDY END
0200066003,AE,    14,4.0,4,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,SCRN,Screening,SCREENING,2013-03-19,2013-04-14,-6.0,21.0,,
0200066003,AE,    14,5.0,14,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-21,2013-05-11,28.0,48.0,,
0200066003,AE,    14,6.0,8,,Conjunctivitis,10010741.0,Conjunctivitis,10010741.0,Eye and eyelid infections,10015909.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DRUG INTERRUPTED,,UNRELATED,OTHER,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,Y,1,SCRN,Screening,SCREENING,2013-03-12,2013-04-20,-13.0,27.0,,
0200066003,AE,    14,7.0,6,,Epigastralgia,10048944.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-09,2013-04-11,16.0,18.0,,
0200066003,AE,    14,8.0,10,,Iliac fossa pain,10021341.0,Abdominal pain lower,10000084.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-17,2013-04-17,24.0,24.0,,
0200066003,AE,    14,9.0,18,,Lipase increased,10024574.0,Lipase increased,10024574.0,Digestive enzymes,10012981.0,Gastrointestinal investigations,10017971.0,Investigations,10022891.0,Investigations,10022891.0,Y,NOT APPLICABLE,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,Y,,4,PTP,Post Treatment Period,POST TREATMENT,2013-06-12,2013-08-07,80.0,136.0,,
0200066003,AE,    14,10.0,11,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-05,2013-05-05,42.0,42.0,,
0200066003,AE,    14,11.0,1,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-29,2013-04-06,5.0,13.0,,
0200066003,AE,    14,12.0,17,,Blood pancreatic amylase increased,10053880.0,Amylase increased,10002016.0,Digestive enzymes,10012981.0,Gastrointestinal investigations,10017971.0,Investigations,10022891.0,Investigations,10022891.0,Y,NOT APPLICABLE,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,Y,,4,PTP,Post Treatment Period,POST TREATMENT,2013-06-12,2013-07-28,80.0,126.0,,
0200066003,AE,    14,13.0,12,,Iliac fossa pain,10021341.0,Abdominal pain lower,10000084.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-05,******,42.0,,AFTER,STUDY END
0200066003,AE,    14,14.0,15,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-07,2013-04-14,14.0,21.0,,
0200066003,AE,    14,15.0,16,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-28,2013-05-06,35.0,43.0,,
0200066003,AE,    14,16.0,13,,Rash trunk,10059872.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-11,2013-04-22,18.0,29.0,,
0200066003,AE,    15,1.0,4,,Bilirubin increased,10004690.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,NONE,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-08-28,2013-09-12,38.0,53.0,,
0200066003,AE,    15,2.0,7,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,PAST INTERCURRENT DISEASE,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-08-28,2013-09-12,38.0,53.0,,
0200066003,AE,    15,3.0,3,,Tumor necrosis,10054101.0,Tumour necrosis,10054094.0,Oncologic complications and emergencies,10030315.0,Neoplasm related morbidities,10068775.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,N,DRUG WITHDRAWN,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-08-28,2013-09-12,38.0,53.0,,
0200066003,AE,    15,4.0,6,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-08-28,2013-09-12,38.0,53.0,,
0200066003,AE,    15,5.0,1,,Ischemic stroke,10055221.0,Ischaemic stroke,10061256.0,Central nervous system haemorrhages and cerebrovascular accidents,10007948.0,Central nervous system vascular disorders,10007963.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DRUG INTERRUPTED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,2013-08-10,7.0,20.0,,
0200066003,AE,    15,6.0,2,,Obstructive jaundice,10029982.0,Jaundice cholestatic,10023129.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-08-28,2013-09-12,38.0,53.0,,
0200066003,AE,    15,7.0,5,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-12,2013-08-27,22.0,37.0,,
0200066003,AE,    16,1.0,7,,Bile duct stenosis,10051341.0,Bile duct stenosis,10051341.0,Obstructive bile duct disorders (excl neoplasms),10029976.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,1,SCRN,Screening,SCREENING,2013-05-18,2013-05-24,-1.0,6.0,,
0200066003,AE,    16,2.0,15,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-02,2013-06-16,15.0,29.0,,
0200066003,AE,    16,3.0,3,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-09-05,82.0,110.0,,
0200066003,AE,    16,4.0,13,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,92.0,,AFTER,STUDY END
0200066003,AE,    16,5.0,1,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-07-28,43.0,71.0,,
0200066003,AE,    16,6.0,14,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-19,2013-05-26,1.0,8.0,,
0200066003,AE,    16,7.0,11,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,92.0,,AFTER,STUDY END
0200066003,AE,    16,8.0,4,,Arthralgia lumbar,10003241.0,Arthralgia,10003239.0,Joint related signs and symptoms,10023226.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-10,******,84.0,,AFTER,STUDY END
0200066003,AE,    16,9.0,16,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-13,2013-07-15,56.0,58.0,,
0200066003,AE,    16,10.0,9,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-02,2013-06-29,15.0,42.0,,
0200066003,AE,    16,11.0,8,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-07-15,43.0,58.0,,
0200066003,AE,    16,12.0,6,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,2013-08-11,71.0,85.0,,
0200066003,AE,    16,13.0,5,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,2013-09-12,92.0,117.0,,
0200066003,AE,    16,14.0,12,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-31,2013-09-12,105.0,117.0,,
0200066003,AE,    16,15.0,10,,Weight loss,10047900.0,Weight decreased,10047895.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-10-25,64.0,160.0,,
0200066003,AE,    17,1.0,1,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-19,******,1.0,,AFTER,STUDY END
0200066003,AE,    17,2.0,5,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-26,******,8.0,,AFTER,STUDY END
0200066003,AE,    17,3.0,7,,Diarrhoea,10012735.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-16,2013-08-30,29.0,43.0,,
0200066003,AE,    17,4.0,6,,Dry skin,10013786.0,Dry skin,10013786.0,Dermal and epidermal conditions NEC,10012424.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-16,21.0,29.0,,
0200066003,AE,    17,5.0,8,,Dyspepsia,10013946.0,Dyspepsia,10013946.0,Dyspeptic signs and symptoms,10013949.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-23,2013-08-30,36.0,43.0,,
0200066003,AE,    17,6.0,13,,Leg edema,10024127.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-09,2013-09,,,,
0200066003,AE,    17,7.0,4,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-16,******,29.0,,AFTER,STUDY END
0200066003,AE,    17,8.0,10,,Hepatic encephalopathy,10019660.0,Hepatic encephalopathy,10019660.0,Encephalopathies toxic and metabolic,10014624.0,Encephalopathies,10014623.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,RELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-10-06,2013-10-10,80.0,84.0,,
0200066003,AE,    17,9.0,12,,Macular puckering,10062977.0,Macular fibrosis,10071392.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-07-18,******,-1.0,,AFTER,STUDY END
0200066003,AE,    17,10.0,9,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-22,21.0,35.0,,
0200066003,AE,    17,11.0,2,,Stomatitis,10042128.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-26,2013-08-02,8.0,15.0,,
0200066003,AE,    17,12.0,11,,Portal vein thrombosis,10036206.0,Portal vein thrombosis,10036206.0,Hepatic vascular disorders,10019712.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,Y,,,Y,2,MPTP,Monotherapy Post Treatment Period,MONOTHERAPY POST TREATMENT,2013-10-11,******,85.0,,AFTER,STUDY END
0200066003,AE,    17,13.0,3,,Fatigue aggravated,10048415.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-16,21.0,29.0,,
0200066003,AE,    18,1.0,4,,Jaundice,10023126.0,Jaundice,10023126.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,******,55.0,,AFTER,STUDY END
0200066003,AE,    18,2.0,2,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-16,2013-07-23,8.0,15.0,,
0200066003,AE,    18,3.0,3,,Epigastric pain,10015026.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-29,******,52.0,,AFTER,STUDY END
0200066003,AE,    18,4.0,1,,Rash both legs,10037851.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-12,2013-07-19,4.0,11.0,,
0200066003,AE,    19,1.0,1,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,NONE,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2013-10-16,2013-10-16,28.0,28.0,,
0200066003,AE,    19,2.0,3,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2013-10-10,2013-10-10,22.0,22.0,,
0200066003,AE,    19,3.0,4,,Low blood pressure,10024895.0,Hypotension,10021097.0,Vascular hypotensive disorders,10057181.0,Decreased and nonspecific blood pressure disorders and shock,10011954.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,2013-10-03,15.0,15.0,,
0200066003,AE,    20,1.0,2,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-08-25,2014-03-16,-7.0,197.0,,
0200066003,AE,    20,2.0,13,,Oedema limbs,10060442.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-04,2013-12-29,34.0,120.0,,
0200066003,AE,    20,3.0,4,,Cataract,10007739.0,Cataract,10007739.0,Cataract conditions,10007772.0,"Anterior eye structural change, deposit and degeneration",10002693.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-08-27,******,-5.0,,AFTER,STUDY END
0200066003,AE,    20,4.0,6,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-04,2013-09-04,4.0,4.0,,
0200066003,AE,    20,5.0,20,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-02,2014-01-02,124.0,124.0,,
0200066003,AE,    20,6.0,18,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-27,2013-11-05,57.0,66.0,,
0200066003,AE,    20,7.0,34,,Eye disorder,10015916.0,Eye disorder,10015916.0,Ocular disorders NEC,10030032.0,Eye disorders NEC,10015917.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DRUG INTERRUPTED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-14,2014-02-22,167.0,175.0,,
0200066003,AE,    20,8.0,16,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-09,2014-05-16,39.0,258.0,,
0200066003,AE,    20,9.0,17,,Hepatic infection,10056522.0,Hepatic infection,10056522.0,Hepatobiliary and spleen infections,10064462.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-09,2013-10-13,39.0,43.0,,
0200066003,AE,    20,10.0,23,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-14,1.0,14.0,,
0200066003,AE,    20,11.0,24,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,Y,,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-14,2013-09-15,14.0,15.0,,
0200066003,AE,    20,12.0,25,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-15,2014-02-02,15.0,155.0,,
0200066003,AE,    20,13.0,26,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,Y,,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-02,2014-02-16,155.0,169.0,,
0200066003,AE,    20,14.0,28,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2014-02-16,2014-03-30,169.0,211.0,,
0200066003,AE,    20,15.0,7,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-06,2013-09-11,6.0,11.0,,
0200066003,AE,    20,16.0,9,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-10-24,22.0,54.0,,
0200066003,AE,    20,17.0,5,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-02,2013-09-07,2.0,7.0,,
0200066003,AE,    20,18.0,30,,Shoulder pain,10040617.0,Musculoskeletal pain,10028391.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2014-02-28,2014-03-16,181.0,197.0,,
0200066003,AE,    20,19.0,29,,Shoulder pain,10040617.0,Musculoskeletal pain,10028391.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2014-02-20,2014-02-27,173.0,180.0,,
0200066003,AE,    20,20.0,10,,Pyrexia,10037660.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG INTERRUPTED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,2013-10-03,33.0,33.0,,
0200066003,AE,    20,21.0,14,,Pyrexia,10037660.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DRUG INTERRUPTED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-09,2013-10-09,39.0,39.0,,
0200066003,AE,    20,22.0,35,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2014-02-28,2014-03-16,181.0,197.0,,
0200066003,AE,    20,23.0,27,,Raised bilirubin,10037805.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2014-02-16,2014-02-28,169.0,181.0,,
0200066003,AE,    20,24.0,31,,Raised bilirubin,10037805.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,,3,PTP,Post Treatment Period,POST TREATMENT,2014-02-28,2014-03-30,181.0,211.0,,
0200066003,AE,    20,25.0,8,,Creatine phosphokinase increased,10011349.0,Blood creatine phosphokinase increased,10005470.0,Skeletal and cardiac muscle analyses,10040768.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-21,2013-09-28,21.0,28.0,,
0200066003,AE,    20,26.0,1,,Rash maculo-papular,10037868.0,Rash maculo-papular,10037868.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,NOT APPLICABLE,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-08-20,2013-08-24,-12.0,-8.0,,
0200066003,AE,    20,27.0,3,,Restless legs,10038742.0,Restless legs syndrome,10058920.0,Sensory abnormalities NEC,10040021.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-08-25,******,-7.0,,AFTER,STUDY END
0200066003,AE,    20,28.0,21,,Rigors,10039177.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-06,2014-02-06,159.0,159.0,,
0200066003,AE,    20,29.0,11,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DRUG INTERRUPTED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,2013-10-03,33.0,33.0,,
0200066003,AE,    20,30.0,15,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DRUG INTERRUPTED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-09,2013-10-09,39.0,39.0,,
0200066003,AE,    20,31.0,19,,Watering eyes,10047848.0,Lacrimation increased,10023644.0,Lacrimation disorders,10072989.0,Eye disorders NEC,10015917.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-11,2013-12-29,72.0,120.0,,
0200066003,AE,    20,32.0,33,,Hands weakness of,10019132.0,Muscular weakness,10028372.0,Muscle weakness conditions,10062913.0,Muscle disorders,10028302.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2014-02-19,2014-02-20,172.0,173.0,,
0200066003,AE,    21,1.0,74,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-18,2014-02-18,210.0,210.0,,
0200066003,AE,    21,2.0,118,,Acholic stool,10057077.0,Faeces pale,10016102.0,Faecal abnormalities NEC,10016097.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-12,259.0,263.0,,
0200066003,AE,    21,3.0,92,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DOSE NOT CHANGED,,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-23,2014-03-25,243.0,245.0,,
0200066003,AE,    21,4.0,117,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,DOSE NOT CHANGED,,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-10,2014-04-16,261.0,267.0,,
0200066003,AE,    21,5.0,155,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DOSE NOT CHANGED,,UNRELATED,MULTIPLE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-25,2014-06-27,337.0,339.0,,
0200066003,AE,    21,6.0,11,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-16,2013-08-16,24.0,24.0,,
0200066003,AE,    21,7.0,95,,Gram-negative bacterial infection NOS,10018657.0,Bacterial infection,10060945.0,Bacterial infections NEC,10004047.0,Bacterial infectious disorders,10004018.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-23,2014-04-02,243.0,253.0,,
0200066003,AE,    21,8.0,90,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,Y,DOSE NOT CHANGED,,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-23,2014-03-25,243.0,245.0,,
0200066003,AE,    21,9.0,108,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-11,259.0,262.0,,
0200066003,AE,    21,10.0,93,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-22,2014-03-23,242.0,243.0,,
0200066003,AE,    21,11.0,107,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,Y,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-07,2014-04-08,258.0,259.0,,
0200066003,AE,    21,12.0,154,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,Y,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-24,336.0,336.0,,
0200066003,AE,    21,13.0,105,,Cholecystitis,10008612.0,Cholecystitis,10008612.0,Cholecystitis and cholelithiasis,10008616.0,Gallbladder disorders,10017628.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DOSE NOT CHANGED,,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-16,259.0,267.0,,
0200066003,AE,    21,14.0,53,,Cough,10011224.0,Cough,10011224.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2014-01-08,160.0,169.0,,
0200066003,AE,    21,15.0,57,,Cough,10011224.0,Cough,10011224.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-08,2014-01-20,169.0,181.0,,
0200066003,AE,    21,16.0,115,,Cough,10011224.0,Cough,10011224.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-03,2014-04-23,254.0,274.0,,
0200066003,AE,    21,17.0,28,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-26,2013-10-26,95.0,95.0,,
0200066003,AE,    21,18.0,40,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-13,2013-12-16,143.0,146.0,,
0200066003,AE,    21,19.0,144,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-07,2014-06-07,319.0,319.0,,
0200066003,AE,    21,20.0,172,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-09,2014-07-13,351.0,355.0,,
0200066003,AE,    21,21.0,185,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-23,2014-08-23,396.0,396.0,,
0200066003,AE,    21,22.0,114,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-16,259.0,267.0,,
0200066003,AE,    21,23.0,89,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-04-02,239.0,253.0,,
0200066003,AE,    21,24.0,159,,Alkaline phosphatase increased,10001675.0,Blood alkaline phosphatase increased,10059570.0,Tissue enzyme analyses NEC,10043891.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-27,336.0,339.0,,
0200066003,AE,    21,25.0,26,,ALT increased,10001845.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-23,87.0,92.0,,
0200066003,AE,    21,26.0,25,,AST increased,10003544.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-23,87.0,92.0,,
0200066003,AE,    21,27.0,152,,Bilirubin increased,10004690.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-27,336.0,339.0,,
0200066003,AE,    21,28.0,29,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-09,2014-01-08,78.0,169.0,,
0200066003,AE,    21,29.0,58,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-08,2014-01-15,169.0,176.0,,
0200066003,AE,    21,30.0,85,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-03-19,176.0,239.0,,
0200066003,AE,    21,31.0,86,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-04-23,239.0,274.0,,
0200066003,AE,    21,32.0,121,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-23,2014-05-07,274.0,288.0,,
0200066003,AE,    21,33.0,127,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,2014-05-21,288.0,302.0,,
0200066003,AE,    21,34.0,137,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-21,2014-05-28,302.0,309.0,,
0200066003,AE,    21,35.0,138,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-28,2014-06-04,309.0,316.0,,
0200066003,AE,    21,36.0,141,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-04,2014-06-18,316.0,330.0,,
0200066003,AE,    21,37.0,146,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-18,2014-06-24,330.0,336.0,,
0200066003,AE,    21,38.0,157,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-27,336.0,339.0,,
0200066003,AE,    21,39.0,165,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-27,2014-07-16,339.0,358.0,,
0200066003,AE,    21,40.0,173,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-16,2014-08-20,358.0,393.0,,
0200066003,AE,    21,41.0,188,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2014-08-27,******,400.0,,AFTER,STUDY END
0200066003,AE,    21,42.0,44,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-18,2013-12-25,148.0,155.0,,
0200066003,AE,    21,43.0,67,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-29,2014-02-05,190.0,197.0,,
0200066003,AE,    21,44.0,87,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-03-23,239.0,243.0,,
0200066003,AE,    21,45.0,96,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-23,2014-03-25,243.0,245.0,,
0200066003,AE,    21,46.0,109,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-11,259.0,262.0,,
0200066003,AE,    21,47.0,128,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,2014-05-13,288.0,294.0,,
0200066003,AE,    21,48.0,156,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-27,336.0,339.0,,
0200066003,AE,    21,49.0,161,,GOT increased,10018624.0,Aspartate aminotransferase increased,10003481.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-27,2014-07-02,339.0,344.0,,
0200066003,AE,    21,50.0,43,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-18,2014-01-01,148.0,162.0,,
0200066003,AE,    21,51.0,68,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-29,2014-02-05,190.0,197.0,,
0200066003,AE,    21,52.0,88,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-03-23,239.0,243.0,,
0200066003,AE,    21,53.0,97,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-23,2014-04-02,243.0,253.0,,
0200066003,AE,    21,54.0,110,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-08,2014-04-11,259.0,262.0,,
0200066003,AE,    21,55.0,158,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-27,336.0,339.0,,
0200066003,AE,    21,56.0,164,,GPT increased,10018644.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-27,2014-07-09,339.0,351.0,,
0200066003,AE,    21,57.0,55,,Expectoration,10058996.0,Productive cough,10036790.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2014-01-10,160.0,171.0,,
0200066003,AE,    21,58.0,189,,Retinal angiosclerosis,10063727.0,Arteriosclerotic retinopathy,10063452.0,Retinopathies NEC,10038932.0,"Retina, choroid and vitreous haemorrhages and vascular disorders",10047060.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-18,******,391.0,,AFTER,STUDY END
0200066003,AE,    21,59.0,46,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,MULTIPLE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-20,2013-12-20,150.0,150.0,,
0200066003,AE,    21,60.0,60,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-10,2014-01-10,171.0,171.0,,
0200066003,AE,    21,61.0,64,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-01-22,176.0,183.0,,
0200066003,AE,    21,62.0,69,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-31,2014-01-31,192.0,192.0,,
0200066003,AE,    21,63.0,78,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-07,2014-03-07,227.0,227.0,,
0200066003,AE,    21,64.0,136,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-15,2014-05-15,296.0,296.0,,
0200066003,AE,    21,65.0,150,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-12,2014-06-12,324.0,324.0,,
0200066003,AE,    21,66.0,170,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-09,2014-07-13,351.0,355.0,,
0200066003,AE,    21,67.0,183,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-20,2014-08-22,393.0,395.0,,
0200066003,AE,    21,68.0,184,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-22,2014-08-23,395.0,396.0,,
0200066003,AE,    21,69.0,9,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-16,2013-08-16,24.0,24.0,,
0200066003,AE,    21,70.0,22,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-18,87.0,87.0,,
0200066003,AE,    21,71.0,45,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-20,2013-12-20,150.0,150.0,,
0200066003,AE,    21,72.0,66,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-31,2014-01-31,192.0,192.0,,
0200066003,AE,    21,73.0,91,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-22,2014-03-23,242.0,243.0,,
0200066003,AE,    21,74.0,106,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-07,2014-04-08,258.0,259.0,,
0200066003,AE,    21,75.0,120,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-18,2014-04-18,269.0,269.0,,
0200066003,AE,    21,76.0,149,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-12,2014-06-12,324.0,324.0,,
0200066003,AE,    21,77.0,153,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-24,2014-06-25,336.0,337.0,,
0200066003,AE,    21,78.0,171,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-11,2014-07-11,353.0,353.0,,
0200066003,AE,    21,79.0,103,,Hematoma injection site,10019432.0,Injection site haematoma,10022066.0,Injection site reactions,10022097.0,Administration site reactions,10001316.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-02,2014-04-16,253.0,267.0,,
0200066003,AE,    21,80.0,13,,Injection site hematoma,10055371.0,Injection site haematoma,10022066.0,Injection site reactions,10022097.0,Administration site reactions,10001316.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,CONCOMITANT MEDICATION,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-27,2014-02-19,35.0,211.0,,
0200066003,AE,    21,81.0,75,,Injection site hematoma,10055371.0,Injection site haematoma,10022066.0,Injection site reactions,10022097.0,Administration site reactions,10001316.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-05,2014-04-02,225.0,253.0,,
0200066003,AE,    21,82.0,140,,Hematoma injection site,10019432.0,Injection site haematoma,10022066.0,Injection site reactions,10022097.0,Administration site reactions,10001316.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,******,288.0,,AFTER,STUDY END
0200066003,AE,    21,83.0,2,,Hemoglobinemia,10019488.0,Haemoglobinaemia,10018901.0,Haemolyses NEC,10018913.0,Haemolyses and related conditions,10018911.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-24,2014-03-05,1.0,225.0,,
0200066003,AE,    21,84.0,125,,Hyperuricemia,10020907.0,Hyperuricaemia,10020903.0,Disorders of purine metabolism,10070968.0,Purine and pyrimidine metabolism disorders,10037546.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-23,2014-04-30,274.0,281.0,,
0200066003,AE,    21,85.0,39,,Hypocalcemia,10020949.0,Hypocalcaemia,10020947.0,Calcium metabolism disorders,10006975.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-11,2013-12-25,141.0,155.0,,
0200066003,AE,    21,86.0,126,,Hypocalcemia,10020949.0,Hypocalcaemia,10020947.0,Calcium metabolism disorders,10006975.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-30,2014-05-07,281.0,288.0,,
0200066003,AE,    21,87.0,5,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-07,2013-08-14,15.0,22.0,,
0200066003,AE,    21,88.0,10,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-21,2013-08-26,29.0,34.0,,
0200066003,AE,    21,89.0,41,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-18,2013-12-25,148.0,155.0,,
0200066003,AE,    21,90.0,56,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-08,2014-01-22,169.0,183.0,,
0200066003,AE,    21,91.0,73,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-19,2014-02-26,211.0,218.0,,
0200066003,AE,    21,92.0,77,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-12,2014-03-19,232.0,239.0,,
0200066003,AE,    21,93.0,98,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-25,2014-03-26,245.0,246.0,,
0200066003,AE,    21,94.0,116,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-11,2014-04-16,262.0,267.0,,
0200066003,AE,    21,95.0,160,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-27,2014-07-02,339.0,344.0,,
0200066003,AE,    21,96.0,167,,Hypokalemia,10021018.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-16,2014-07-23,358.0,365.0,,
0200066003,AE,    21,97.0,16,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-10-09,57.0,78.0,,
0200066003,AE,    21,98.0,33,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-20,2013-12-11,120.0,141.0,,
0200066003,AE,    21,99.0,47,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-25,2014-01-08,155.0,169.0,,
0200066003,AE,    21,100.0,63,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-01-22,176.0,183.0,,
0200066003,AE,    21,101.0,82,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-03-25,239.0,245.0,,
0200066003,AE,    21,102.0,113,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-09,******,260.0,,AFTER,STUDY END
0200066003,AE,    21,103.0,177,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-23,2014-07-30,365.0,372.0,,
0200066003,AE,    21,104.0,182,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-13,2014-08-20,386.0,393.0,,
0200066003,AE,    21,105.0,24,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-23,87.0,92.0,,
0200066003,AE,    21,106.0,27,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-23,2013-10-30,92.0,99.0,,
0200066003,AE,    21,107.0,34,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-27,2013-12-11,127.0,141.0,,
0200066003,AE,    21,108.0,48,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-25,2014-02-19,155.0,211.0,,
0200066003,AE,    21,109.0,76,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-12,2014-04-30,232.0,281.0,,
0200066003,AE,    21,110.0,131,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,2014-05-28,288.0,309.0,,
0200066003,AE,    21,111.0,148,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-18,2014-06-27,330.0,339.0,,
0200066003,AE,    21,112.0,163,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-02,2014-07-23,344.0,365.0,,
0200066003,AE,    21,113.0,176,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-30,2014-08-06,372.0,379.0,,
0200066003,AE,    21,114.0,19,,Drug overdose,10068719.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-26,2013-07-26,3.0,3.0,,
0200066003,AE,    21,115.0,14,,Renal infarct,10038470.0,Renal infarct,10038470.0,Renal vascular and ischaemic conditions,10038543.0,Renal disorders (excl nephropathies),10038430.0,Renal and urinary disorders,10038359.0,Renal and urinary disorders,10038359.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-24,******,1.0,,AFTER,STUDY END
0200066003,AE,    21,116.0,21,,Injection site reaction,10022095.0,Injection site reaction,10022095.0,Injection site reactions,10022097.0,Administration site reactions,10001316.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,CONCOMITANT MEDICATION,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-15,2014-02-19,84.0,211.0,,
0200066003,AE,    21,117.0,151,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-15,******,327.0,,AFTER,STUDY END
0200066003,AE,    21,118.0,59,,Expectoration,10058996.0,Productive cough,10036790.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-10,2014-01-20,171.0,181.0,,
0200066003,AE,    21,119.0,81,,Gastric pain,10017814.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-14,******,234.0,,AFTER,STUDY END
0200066003,AE,    21,120.0,94,,Meteorism,10027493.0,Abdominal distension,10000060.0,"Flatulence, bloating and distension",10016770.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-22,2014-03-25,242.0,245.0,,
0200066003,AE,    21,121.0,111,,Meteorism,10027493.0,Abdominal distension,10000060.0,"Flatulence, bloating and distension",10016770.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-07,2014-06-04,258.0,316.0,,
0200066003,AE,    21,122.0,4,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-31,2013-08-07,8.0,15.0,,
0200066003,AE,    21,123.0,31,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-06,2013-11-13,106.0,113.0,,
0200066003,AE,    21,124.0,37,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-27,2013-12-04,127.0,134.0,,
0200066003,AE,    21,125.0,38,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-04,2013-12-11,134.0,141.0,,
0200066003,AE,    21,126.0,50,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-25,2014-01-01,155.0,162.0,,
0200066003,AE,    21,127.0,52,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-01,2014-01-08,162.0,169.0,,
0200066003,AE,    21,128.0,61,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-01-22,176.0,183.0,,
0200066003,AE,    21,129.0,72,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-19,2014-02-26,211.0,218.0,,
0200066003,AE,    21,130.0,100,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-25,2014-03-26,245.0,246.0,,
0200066003,AE,    21,131.0,101,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-26,2014-04-02,246.0,253.0,,
0200066003,AE,    21,132.0,123,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-23,2014-04-30,274.0,281.0,,
0200066003,AE,    21,133.0,130,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,2014-05-13,288.0,294.0,,
0200066003,AE,    21,134.0,135,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-21,2014-05-28,302.0,309.0,,
0200066003,AE,    21,135.0,143,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-04,2014-06-10,316.0,322.0,,
0200066003,AE,    21,136.0,169,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-16,2014-07-23,358.0,365.0,,
0200066003,AE,    21,137.0,175,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-30,2014-08-13,372.0,386.0,,
0200066003,AE,    21,138.0,180,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-13,2014-08-20,386.0,393.0,,
0200066003,AE,    21,139.0,187,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2014-08-27,2014-09-16,400.0,420.0,,
0200066003,AE,    21,140.0,3,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-31,2013-08-07,8.0,15.0,,
0200066003,AE,    21,141.0,6,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-14,2013-08-21,22.0,29.0,,
0200066003,AE,    21,142.0,7,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-21,2013-08-26,29.0,34.0,,
0200066003,AE,    21,143.0,17,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-25,2013-10-02,64.0,71.0,,
0200066003,AE,    21,144.0,32,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-06,2013-11-13,106.0,113.0,,
0200066003,AE,    21,145.0,36,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-27,2013-12-11,127.0,141.0,,
0200066003,AE,    21,146.0,42,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-18,2013-12-25,148.0,155.0,,
0200066003,AE,    21,147.0,51,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-25,2014-01-08,155.0,169.0,,
0200066003,AE,    21,148.0,62,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-01-22,176.0,183.0,,
0200066003,AE,    21,149.0,70,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-12,2014-02-26,204.0,218.0,,
0200066003,AE,    21,150.0,83,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-03-22,239.0,242.0,,
0200066003,AE,    21,151.0,99,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-25,2014-03-26,245.0,246.0,,
0200066003,AE,    21,152.0,122,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-23,2014-04-30,274.0,281.0,,
0200066003,AE,    21,153.0,129,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-07,2014-05-13,288.0,294.0,,
0200066003,AE,    21,154.0,134,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-21,2014-05-28,302.0,309.0,,
0200066003,AE,    21,155.0,142,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-04,2014-06-10,316.0,322.0,,
0200066003,AE,    21,156.0,174,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-30,2014-08-06,372.0,379.0,,
0200066003,AE,    21,157.0,179,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-06,2014-08-20,379.0,393.0,,
0200066003,AE,    21,158.0,186,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2014-08-27,2014-09-16,400.0,420.0,,
0200066003,AE,    21,159.0,80,,Oesophageal reflux,10030182.0,Gastrooesophageal reflux disease,10017885.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-14,2014-03-23,234.0,243.0,,
0200066003,AE,    21,160.0,12,,Inflammation localized,10021959.0,Inflammation,10061218.0,Inflammations,10021950.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-19,2013-08-24,27.0,32.0,,
0200066003,AE,    21,161.0,15,,Throat pain,10043523.0,Oropharyngeal pain,10068319.0,Upper respiratory tract signs and symptoms,10046313.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-06,2013-09-07,45.0,46.0,,
0200066003,AE,    21,162.0,54,,Throat pain,10043523.0,Oropharyngeal pain,10068319.0,Upper respiratory tract signs and symptoms,10046313.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2014-01-08,160.0,169.0,,
0200066003,AE,    21,163.0,145,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-10,2014-06-24,322.0,336.0,,
0200066003,AE,    21,164.0,168,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-16,2014-07-23,358.0,365.0,,
0200066003,AE,    21,165.0,178,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-06,2014-08-20,379.0,393.0,,
0200066003,AE,    21,166.0,8,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-21,2013-08-26,29.0,34.0,,
0200066003,AE,    21,167.0,30,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-30,2013-11-13,99.0,113.0,,
0200066003,AE,    21,168.0,35,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-27,2013-12-11,127.0,141.0,,
0200066003,AE,    21,169.0,49,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-25,2014-01-08,155.0,169.0,,
0200066003,AE,    21,170.0,65,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-22,2014-01-29,183.0,190.0,,
0200066003,AE,    21,171.0,71,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-19,2014-02-26,211.0,218.0,,
0200066003,AE,    21,172.0,79,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-12,2014-04-02,232.0,253.0,,
0200066003,AE,    21,173.0,124,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-23,2014-04-30,274.0,281.0,,
0200066003,AE,    21,174.0,132,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-13,2014-05-28,294.0,309.0,,
0200066003,AE,    21,175.0,84,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-12,2014-04-02,232.0,253.0,,
0200066003,AE,    21,176.0,112,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-09,2014-04-11,260.0,262.0,,
0200066003,AE,    21,177.0,119,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-16,2014-04-30,267.0,281.0,,
0200066003,AE,    21,178.0,133,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-21,2014-05-28,302.0,309.0,,
0200066003,AE,    21,179.0,139,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-04,2014-06-27,316.0,339.0,,
0200066003,AE,    21,180.0,162,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-06-27,2014-07-02,339.0,344.0,,
0200066003,AE,    21,181.0,166,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-07-09,2014-08-06,351.0,379.0,,
0200066003,AE,    21,182.0,181,,Unspecified anemia,10045627.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-08-13,2014-08-27,386.0,400.0,,
0200066003,AE,    21,183.0,23,,Urinary infection,10046544.0,Urinary tract infection,10046571.0,Urinary tract infections,10046577.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-23,87.0,92.0,,
0200066003,AE,    21,184.0,104,,Vitamin D decreased,10062189.0,Vitamin D decreased,10062189.0,Vitamin analyses,10047598.0,"Metabolic, nutritional and blood gas investigations",10027432.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-25,******,245.0,,AFTER,STUDY END
0200066003,AE,    21,185.0,102,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-04-01,2014-04-01,252.0,252.0,,
0200066003,AE,    21,186.0,20,,Watering eyes,10047848.0,Lacrimation increased,10023644.0,Lacrimation disorders,10072989.0,Eye disorders NEC,10015917.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-15,2013-12-04,84.0,134.0,,
0200066003,AE,    21,187.0,18,,White blood cell decreased,10049182.0,White blood cell count decreased,10047942.0,White blood cell analyses,10047938.0,Haematology investigations (incl blood groups),10018851.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-25,2013-10-02,64.0,71.0,,
0200066003,AE,    23,1.0,4,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-03,2013-11-14,8.0,80.0,,
0200066003,AE,    23,2.0,2,,Debility,10011942.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-31,2013-09-02,5.0,7.0,,
0200066003,AE,    23,3.0,14,,Debility,10011942.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-04,2013-09-05,9.0,10.0,,
0200066003,AE,    23,4.0,7,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-07,2013-11-25,12.0,91.0,,
0200066003,AE,    23,5.0,5,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,,,,,,,,,3,SCRN,Screening,SCREENING,2013-08-21,2013-08-26,-6.0,-1.0,,
0200066003,AE,    23,6.0,6,,Glucose increased,10018421.0,Blood glucose increased,10005557.0,Carbohydrate tolerance analyses (incl diabetes),10007217.0,"Metabolic, nutritional and blood gas investigations",10027432.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-10,******,15.0,,AFTER,STUDY END
0200066003,AE,    23,7.0,1,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-28,2013-11-27,2.0,93.0,,
0200066003,AE,    23,8.0,22,,Catheter infection,10051387.0,Device related infection,10064687.0,Infections NEC,10021902.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-10,2013-09-22,15.0,27.0,,
0200066003,AE,    23,9.0,23,,Catheter infection,10051387.0,Device related infection,10064687.0,Infections NEC,10021902.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-23,2013-09-24,28.0,29.0,,
0200066003,AE,    23,10.0,20,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-08,2013-10-08,43.0,43.0,,
0200066003,AE,    24,1.0,2,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-29,2013-07-01,1.0,3.0,,
0200066003,AE,    24,2.0,3,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-02,2013-07-12,4.0,14.0,,
0200066003,AE,    24,3.0,4,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DRUG WITHDRAWN,LED TO STUDY TERMINATION,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-13,2013-09-15,15.0,79.0,,
0200066003,AE,    24,4.0,5,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DRUG WITHDRAWN,LED TO STUDY TERMINATION,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-12,2013-09-15,14.0,79.0,,
0200066003,AE,    24,5.0,1,,Dyspnea,10013963.0,Dyspnoea,10013968.0,Breathing abnormalities,10006334.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-09-15,2.0,79.0,,
0200066003,AE,    25,1.0,6,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-10,2014-01-07,99.0,127.0,,
0200066003,AE,    25,2.0,7,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2014-02-06,2014-02-06,157.0,157.0,,
0200066003,AE,    25,3.0,11,,Esophagitis,10015461.0,Oesophagitis,10030216.0,Oesophagitis (excl infective),10053171.0,Gastrointestinal inflammatory conditions,10017969.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-01-15,******,135.0,,AFTER,STUDY END
0200066003,AE,    25,4.0,8,,General physical health deterioration,10049438.0,General physical health deterioration,10049438.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,,UNRELATED,NONE,FATAL,,,Y,,,,Y,5,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-01-22,2014-02-06,142.0,157.0,,
0200066003,AE,    25,5.0,14,,Hyperkalemia,10020647.0,Hyperkalaemia,10020646.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-27,2013-12-03,86.0,92.0,,
0200066003,AE,    25,6.0,13,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-01-22,******,142.0,,AFTER,STUDY END
0200066003,AE,    25,7.0,2,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-17,2013-10-01,15.0,29.0,,
0200066003,AE,    25,8.0,3,,Leukopenia,10024384.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-08,2013-10-15,36.0,43.0,,
0200066003,AE,    25,9.0,9,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-17,2013-10-01,15.0,29.0,,
0200066003,AE,    25,10.0,10,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-08,2013-10-15,36.0,43.0,,
0200066003,AE,    25,11.0,5,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-10,2013-12-17,99.0,106.0,,
0200066003,AE,    25,12.0,12,,Serous detachment of the macula,10062968.0,Macular detachment,10075873.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-01-15,******,135.0,,AFTER,STUDY END
0200066003,AE,    26,1.0,6,,Cold,10009851.0,Nasopharyngitis,10028810.0,Upper respiratory tract infections,10046309.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-01,2013-10-05,93.0,97.0,,
0200066003,AE,    26,2.0,9,,Cold,10009851.0,Nasopharyngitis,10028810.0,Upper respiratory tract infections,10046309.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-26,2013-12-07,149.0,160.0,,
0200066003,AE,    26,3.0,5,,Edema of lower extremities,10054498.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-20,2013-11-08,82.0,131.0,,
0200066003,AE,    26,4.0,11,,Headache,10019211.0,Headache,10019211.0,Headaches NEC,10019233.0,Headaches,10019231.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-20,2013-12-20,173.0,173.0,,
0200066003,AE,    26,5.0,8,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-26,2013-10-26,118.0,118.0,,
0200066003,AE,    26,6.0,12,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,,RELATED,NONE,,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-31,2014-02-03,184.0,218.0,,
0200066003,AE,    26,7.0,1,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-03,2013-07-04,3.0,4.0,,
0200066003,AE,    26,8.0,2,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-09,2013-07-11,9.0,11.0,,
0200066003,AE,    26,9.0,7,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-07,2013-10-09,99.0,101.0,,
0200066003,AE,    26,10.0,10,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-15,2013-12-15,168.0,168.0,,
0200066003,AE,    26,11.0,4,,Serous retinal detachment,10040114.0,Retinal detachment,10038848.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,Y,DRUG INTERRUPTED,NONE,RELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,Y,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-04,2013-09-19,66.0,81.0,,
0200066003,AE,    26,12.0,14,,Glaucoma aggravated,10048354.0,Glaucoma,10018304.0,Glaucomas (excl congenital),10018305.0,Glaucoma and ocular hypertension,10018307.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-31,2013-09-05,31.0,67.0,,
0200066003,AE,    26,13.0,13,,Hypertension worsened,10020799.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DRUG WITHDRAWN,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2014-02-03,2014-03-28,218.0,271.0,,
0200066003,AE,    27,1.0,18,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-07,******,134.0,,AFTER,STUDY END
0200066003,AE,    27,2.0,9,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-08,2013-08-03,43.0,99.0,,
0200066003,AE,    27,3.0,12,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-03,2013-09-28,99.0,155.0,,
0200066003,AE,    27,4.0,16,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DRUG INTERRUPTED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-28,******,155.0,,AFTER,STUDY END
0200066003,AE,    27,5.0,1,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,MULTIPLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-05,2013-05-06,9.0,10.0,,
0200066003,AE,    27,6.0,7,,Peripheral edema,10034570.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-25,2013-06-22,29.0,57.0,,
0200066003,AE,    27,7.0,11,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-05,2013-06-08,40.0,43.0,,
0200066003,AE,    27,8.0,3,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-05,2013-05-05,9.0,9.0,,
0200066003,AE,    27,9.0,4,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-12,2013-05-14,16.0,18.0,,
0200066003,AE,    27,10.0,6,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-25,2013-06-04,29.0,39.0,,
0200066003,AE,    27,11.0,10,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,UNPLAN,,TREATMENT,2013-07-06,2013-08-03,71.0,99.0,,
0200066003,AE,    27,12.0,17,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,MULTIPLE,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-21,******,148.0,,AFTER,STUDY END
0200066003,AE,    27,13.0,2,,Drowsiness,10013649.0,Somnolence,10041349.0,Disturbances in consciousness NEC,10013509.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-05,2013-05-06,9.0,10.0,,
0200066003,AE,    27,14.0,5,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-14,2013-05-16,18.0,20.0,,
0200066003,AE,    27,15.0,14,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-27,******,92.0,,AFTER,STUDY END
0200066003,AE,    27,16.0,13,,Hair loss,10019045.0,Alopecia,10001760.0,Alopecias,10001769.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-03,******,99.0,,AFTER,STUDY END
0200066003,AE,    27,17.0,19,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,FU,Follow-up Period,FOLLOW-UP,2013-11-16,******,204.0,,AFTER,STUDY END
0200066003,AE,    27,18.0,15,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-27,2013-09-07,92.0,134.0,,
0200066003,AE,    27,19.0,8,,Visual disturbances,10047545.0,Visual impairment,10047571.0,Visual disorders NEC,10047541.0,Vision disorders,10047518.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DRUG INTERRUPTED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,UNPLAN,,TREATMENT,2013-06-23,2013-06-24,58.0,59.0,,
0200066003,AE,    27,20.0,20,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,FU,Follow-up Period,FOLLOW-UP,2013-11-16,******,204.0,,AFTER,STUDY END
0200066003,AE,    28,1.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-02,2013-11-11,8.0,17.0,,
0200066003,AE,    29,1.0,6,,Anemia aggravated,10054309.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,UNKNOWN,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-14,******,1.0,,U,STUDY END
0200066003,AE,    29,2.0,4,,Bilirubin increased,10004690.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-14,2013-07-27,1.0,14.0,,
0200066003,AE,    29,3.0,7,,Bilirubin increased,10004690.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,UNKNOWN,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,******,15.0,,U,STUDY END
0200066003,AE,    29,4.0,2,,Creatinine increased,10011368.0,Blood creatinine increased,10005483.0,Renal function analyses,10038454.0,Renal and urinary tract investigations and urinalyses,10038362.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,UNKNOWN,,,,,,,,1,SCRN,Screening,SCREENING,2013-07-02,******,-12.0,,U,STUDY END
0200066003,AE,    29,5.0,11,,Fatigue aggravated,10048415.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,UNKNOWN,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2013-07-31,******,18.0,,U,STUDY END
0200066003,AE,    29,6.0,16,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-07-21,8.0,8.0,,
0200066003,AE,    29,7.0,8,,Hepatic enzyme increased,10060795.0,Hepatic enzyme increased,10060795.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,UNKNOWN,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,******,15.0,,U,STUDY END
0200066003,AE,    29,8.0,1,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,NONE,UNRELATED,PAST INTERCURRENT DISEASE,UNKNOWN,,,,,,,,2,SCRN,Screening,SCREENING,2013-07-02,******,-12.0,,U,STUDY END
0200066003,AE,    29,9.0,15,,Hypomagnesemia,10021028.0,Hypomagnesaemia,10021027.0,Magnesium metabolism disorders,10025439.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,UNKNOWN,,,,,,,Y,2,SCRN,Screening,SCREENING,2013-07-02,******,-12.0,,U,STUDY END
0200066003,AE,    29,10.0,3,,Sinus tachycardia,10040752.0,Sinus tachycardia,10040752.0,Supraventricular arrhythmias,10042600.0,Cardiac arrhythmias,10007521.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PAST INTERCURRENT DISEASE,UNKNOWN,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-14,******,1.0,,U,STUDY END
0200066003,AE,    29,11.0,14,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,UNKNOWN,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-14,******,1.0,,U,STUDY END
0200066003,AE,    29,12.0,9,,Pyrosis,10037676.0,Dyspepsia,10013946.0,Dyspeptic signs and symptoms,10013949.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-19,2013-07-28,6.0,15.0,,
0200066003,AE,    29,13.0,5,,Swelling of R knee,10042704.0,Joint swelling,10023232.0,Joint related signs and symptoms,10023226.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,SCRN,Screening,SCREENING,2013-07-12,2013-07-15,-2.0,2.0,,
0200066003,AE,    29,14.0,10,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PROTOCOL PROCEDURE,UNKNOWN,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,******,8.0,,U,STUDY END
0200066003,AE,    29,15.0,12,,General physical health deterioration,10049438.0,General physical health deterioration,10049438.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-08-03,2013-08-11,21.0,29.0,,
0200066003,AE,    30,1.0,2,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,******,8.0,,AFTER,STUDY END
0200066003,AE,    30,2.0,3,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,2013-04-28,8.0,42.0,,
0200066003,AE,    30,3.0,11,,Asthenia,10003549.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2013-04-29,******,43.0,,AFTER,STUDY END
0200066003,AE,    30,4.0,12,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,NONE,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2013-04-30,2013-04-30,44.0,44.0,,
0200066003,AE,    30,5.0,9,,Depression,10012378.0,Depression,10012378.0,Depressive disorders,10012401.0,Depressed mood disorders and disturbances,10012375.0,Psychiatric disorders,10037175.0,Psychiatric disorders,10037175.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-04-29,******,43.0,,AFTER,STUDY END
0200066003,AE,    30,6.0,5,,Dyspnea,10013963.0,Dyspnoea,10013968.0,Breathing abnormalities,10006334.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,******,8.0,,AFTER,STUDY END
0200066003,AE,    30,7.0,1,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-19,2013-03-20,2.0,3.0,,
0200066003,AE,    30,8.0,7,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DRUG INTERRUPTED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-26,2013-04-08,9.0,22.0,,
0200066003,AE,    30,9.0,4,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,******,8.0,,AFTER,STUDY END
0200066003,AE,    30,10.0,10,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DRUG INTERRUPTED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-01,******,15.0,,AFTER,STUDY END
0200066003,AE,    30,11.0,6,,Peripheral edema,10034570.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-25,******,8.0,,AFTER,STUDY END
0200066003,AE,    30,12.0,8,,Weight loss,10047900.0,Weight decreased,10047895.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-04-22,******,36.0,,AFTER,STUDY END
0200066003,AE,    31,1.0,1,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,SCRN,Screening,SCREENING,2013-09-15,2013-09-18,-3.0,1.0,,
0200066003,AE,    31,2.0,3,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-09-19,1.0,2.0,,
0200066003,AE,    31,3.0,9,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-09-26,5.0,9.0,,
0200066003,AE,    31,4.0,7,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-09-26,5.0,9.0,,
0200066003,AE,    31,5.0,27,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-31,2013-11,44.0,,,
0200066003,AE,    31,6.0,15,,Bloodshot eye,10005871.0,Ocular hyperaemia,10030041.0,"Ocular infections, inflammations and associated manifestations",10030045.0,"Ocular infections, irritations and inflammations",10021877.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DRUG INTERRUPTED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,2013-10-07,16.0,20.0,,
0200066003,AE,    31,7.0,17,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,Y,1,SCRN,Screening,SCREENING,2013-09,2013-09,,,,
0200066003,AE,    31,8.0,26,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,CONCOMITANT MEDICATION,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-21,2013-11-06,34.0,50.0,,
0200066003,AE,    31,9.0,18,,Urination difficulty,10046599.0,Dysuria,10013990.0,Bladder and urethral symptoms,10004995.0,Urinary tract signs and symptoms,10046590.0,Renal and urinary disorders,10038359.0,Renal and urinary disorders,10038359.0,N,DOSE NOT CHANGED,,UNRELATED,MULTIPLE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-27,2013-11,10.0,,,
0200066003,AE,    31,10.0,33,,Urination difficulty,10046599.0,Dysuria,10013990.0,Bladder and urethral symptoms,10004995.0,Urinary tract signs and symptoms,10046590.0,Renal and urinary disorders,10038359.0,Renal and urinary disorders,10038359.0,Y,DRUG WITHDRAWN,,UNRELATED,MULTIPLE,RECOVERED/RESOLVED,,,,Y,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11,2013-11,,,,
0200066003,AE,    31,11.0,25,,Dry mouth,10013781.0,Dry mouth,10013781.0,Oral dryness and saliva altered,10030975.0,Salivary gland conditions,10039404.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-25,2013-11,38.0,,,
0200066003,AE,    31,12.0,10,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-09-25,5.0,8.0,,
0200066003,AE,    31,13.0,20,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-28,2013-09-29,11.0,12.0,,
0200066003,AE,    31,14.0,16,,Throat irritation,10043521.0,Throat irritation,10043521.0,Upper respiratory tract signs and symptoms,10046313.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,2013-10-25,16.0,38.0,,
0200066003,AE,    31,15.0,32,,Neutrophil count low,10029369.0,Neutrophil count decreased,10029366.0,White blood cell analyses,10047938.0,Haematology investigations (incl blood groups),10018851.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-04,2013-10-10,17.0,23.0,,
0200066003,AE,    31,16.0,31,,White blood cell count low,10051617.0,White blood cell count decreased,10047942.0,White blood cell analyses,10047938.0,Haematology investigations (incl blood groups),10018851.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-31,2013-11,44.0,,,
0200066003,AE,    31,17.0,29,,Low back pain,10024891.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,Y,DRUG INTERRUPTED,,RELATED,DISEASE UNDER STUDY,,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-03,2013-11-10,47.0,54.0,,
0200066003,AE,    31,18.0,5,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-09-19,1.0,2.0,,
0200066003,AE,    31,19.0,13,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-27,2013-10-04,10.0,17.0,,
0200066003,AE,    31,20.0,14,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-04,2013-10-04,17.0,17.0,,
0200066003,AE,    31,21.0,11,,Night sweats,10029410.0,Night sweats,10029410.0,Apocrine and eccrine gland disorders,10002982.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-10-04,1.0,17.0,,
0200066003,AE,    31,22.0,19,,Night sweats,10029410.0,Night sweats,10029410.0,Apocrine and eccrine gland disorders,10002982.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013,31.0,,,
0200066003,AE,    31,23.0,6,,Oral thrush,10031026.0,Oral candidiasis,10030963.0,Candida infections,10007134.0,Fungal infectious disorders,10017528.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-10-26,5.0,39.0,,
0200066003,AE,    31,24.0,23,,Upper abdominal pain,10046272.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-16,2013-10-25,29.0,38.0,,
0200066003,AE,    31,25.0,8,,Pain in hip,10033432.0,Arthralgia,10003239.0,Joint related signs and symptoms,10023226.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-22,2013-09-26,5.0,9.0,,
0200066003,AE,    31,26.0,24,,Pain in hip,10033432.0,Arthralgia,10003239.0,Joint related signs and symptoms,10023226.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10,2013-10-26,,39.0,,
0200066003,AE,    31,27.0,30,,Gamma-glutamyltransferase increased,10017693.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-11-19,31.0,63.0,,
0200066003,AE,    31,28.0,4,,Shoulder pain,10040617.0,Musculoskeletal pain,10028391.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-09-28,1.0,11.0,,
0200066003,AE,    31,29.0,2,,Vomited,10047699.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-18,2013-09-18,1.0,1.0,,
0200066003,AE,    31,30.0,12,,Vomited,10047699.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-26,2013-09-26,9.0,9.0,,
0200066003,AE,    31,31.0,22,,Vomited,10047699.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-10,2013-10-10,23.0,23.0,,
0200066003,AE,    31,32.0,21,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-02,2013-10-03,15.0,16.0,,
0200066003,AE,    31,33.0,28,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,Y,5,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-03,2013-11-19,47.0,63.0,,
0200066003,AE,    32,1.0,7,,Bronchitis,10006451.0,Bronchitis,10006451.0,Lower respiratory tract and lung infections,10025101.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,Y,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-30,2013-08-06,84.0,91.0,,
0200066003,AE,    32,2.0,14,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-06-04,15.0,28.0,,
0200066003,AE,    32,3.0,22,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-05,2013-06-19,29.0,43.0,,
0200066003,AE,    32,4.0,16,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-20,******,44.0,,AFTER,STUDY END
0200066003,AE,    32,5.0,18,,Dizziness,10013573.0,Dizziness,10013573.0,Neurological signs and symptoms NEC,10029306.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-03,2013-06-20,27.0,44.0,,
0200066003,AE,    32,6.0,1,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-09,2013-06-04,2.0,28.0,,
0200066003,AE,    32,7.0,2,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-05,2013-06-19,29.0,43.0,,
0200066003,AE,    32,8.0,3,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-20,******,44.0,,AFTER,STUDY END
0200066003,AE,    32,9.0,6,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-20,2013-06-20,44.0,44.0,,
0200066003,AE,    32,10.0,25,,Phlebitis lower limb,10051996.0,Phlebitis,10034879.0,Phlebitis NEC,10052780.0,Vascular inflammations,10047116.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08,******,,,AFTER,STUDY END
0200066003,AE,    32,11.0,13,,Folliculitis,10016936.0,Folliculitis,10016936.0,Bacterial infections NEC,10004047.0,Bacterial infectious disorders,10004018.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-05-29,15.0,22.0,,
0200066003,AE,    32,12.0,23,,Gum bleeding,10018771.0,Gingival bleeding,10018276.0,Gingival haemorrhages,10055797.0,Dental and gingival conditions,10044018.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-08,2013-05,1.0,,,
0200066003,AE,    32,13.0,17,,Haemorrhoids,10019022.0,Haemorrhoids,10019022.0,Haemorrhoids and gastrointestinal varices (excl oesophageal),10018029.0,Gastrointestinal vascular conditions,10018031.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-06-20,15.0,44.0,,
0200066003,AE,    32,14.0,8,,Hoarseness,10020201.0,Dysphonia,10013952.0,Upper respiratory tract signs and symptoms,10046313.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-13,2013-05-22,6.0,15.0,,
0200066003,AE,    32,15.0,24,,Itchy legs,10023091.0,Pruritus,10037087.0,Pruritus NEC,10049293.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-06,15.0,,,
0200066003,AE,    32,16.0,26,,Iron low,10022982.0,Blood iron decreased,10005619.0,Mineral and electrolyte analyses,10027637.0,"Water, electrolyte and mineral investigations",10047843.0,Investigations,10022891.0,Investigations,10022891.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-08-05,******,90.0,,AFTER,STUDY END
0200066003,AE,    32,17.0,4,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-11,2013-07-30,4.0,84.0,,
0200066003,AE,    32,18.0,12,,Chest pressure,10008486.0,Chest discomfort,10008469.0,Pain and discomfort NEC,10033372.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-18,2013-05-18,11.0,11.0,,
0200066003,AE,    32,19.0,9,,Pruritus,10037087.0,Pruritus,10037087.0,Pruritus NEC,10049293.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-13,2013-05-22,6.0,15.0,,
0200066003,AE,    32,20.0,11,,Stomach pain,10042112.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-06-12,15.0,36.0,,
0200066003,AE,    32,21.0,5,,Slight fever,10041021.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-09,2013-07-29,2.0,83.0,,
0200066003,AE,    32,22.0,10,,Night sweats,10029410.0,Night sweats,10029410.0,Apocrine and eccrine gland disorders,10002982.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-14,2013-05-14,7.0,7.0,,
0200066003,AE,    32,23.0,19,,Taste alteration,10043125.0,Dysgeusia,10013911.0,Sensory abnormalities NEC,10040021.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-11,2013-08-21,65.0,106.0,,
0200066003,AE,    32,24.0,20,,Abdominal pain aggravated,10048358.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-01,******,86.0,,AFTER,STUDY END
0200066003,AE,    33,1.0,13,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-08,******,108.0,,AFTER,STUDY END
0200066003,AE,    33,2.0,14,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-08,******,108.0,,AFTER,STUDY END
0200066003,AE,    33,3.0,9,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-23,2013-11-07,92.0,107.0,,
0200066003,AE,    33,4.0,11,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-08,******,108.0,,AFTER,STUDY END
0200066003,AE,    33,5.0,1,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-26,2013-07-26,3.0,3.0,,
0200066003,AE,    33,6.0,8,,Flu syndrome,10016793.0,Influenza,10022000.0,Influenza viral infections,10022005.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-23,2013-10-25,92.0,94.0,,
0200066003,AE,    33,7.0,16,,Hand and foot syndrome,10019111.0,Palmar-plantar erythrodysaesthesia syndrome,10033553.0,Skin and subcutaneous conditions NEC,10042356.0,Skin and subcutaneous tissue disorders NEC,10040790.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-07,******,107.0,,AFTER,STUDY END
0200066003,AE,    33,8.0,6,,Obstructive jaundice,10029982.0,Jaundice cholestatic,10023129.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-18,2013-12-01,118.0,131.0,,
0200066003,AE,    33,9.0,2,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-25,2013-07-26,2.0,3.0,,
0200066003,AE,    33,10.0,10,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-23,2013-11-07,92.0,107.0,,
0200066003,AE,    33,11.0,12,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-08,******,108.0,,AFTER,STUDY END
0200066003,AE,    33,12.0,4,,Papular rash,10033726.0,Rash papular,10037876.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-29,2013-08-02,6.0,10.0,,
0200066003,AE,    33,13.0,5,,Papular rash,10033726.0,Rash papular,10037876.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-03,2013-08-10,11.0,18.0,,
0200066003,AE,    33,14.0,17,,Itchy skin,10023094.0,Pruritus,10037087.0,Pruritus NEC,10049293.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-11-19,******,119.0,,AFTER,STUDY END
0200066003,AE,    33,15.0,3,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-25,2013-07-26,2.0,3.0,,
0200066003,AE,    33,16.0,7,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-23,2013-10-24,92.0,93.0,,
0200066003,AE,    33,17.0,15,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-08,******,108.0,,AFTER,STUDY END
0200066003,AE,    34,1.0,31,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,2013-08-04,211.0,218.0,,
0200066003,AE,    34,2.0,37,,Rash acneiform,10037847.0,Dermatitis acneiform,10012432.0,Acnes,10000497.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,232.0,,AFTER,STUDY END
0200066003,AE,    34,3.0,10,,Rash acneiform,10037847.0,Dermatitis acneiform,10012432.0,Acnes,10000497.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-02-10,2013-02-24,43.0,57.0,,
0200066003,AE,    34,4.0,19,,Alopecia,10001760.0,Alopecia,10001760.0,Alopecias,10001769.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-21,******,113.0,,AFTER,STUDY END
0200066003,AE,    34,5.0,11,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-06,2013-03-10,8.0,71.0,,
0200066003,AE,    34,6.0,17,,Gonarthrosis,10048794.0,Osteoarthritis,10031161.0,Osteoarthropathies,10057178.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-21,******,113.0,,AFTER,STUDY END
0200066003,AE,    34,7.0,2,,Back pain,10003988.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,SCRN,Screening,SCREENING,2012-12-24,2013-01-27,-6.0,29.0,,
0200066003,AE,    34,8.0,30,,Gum bleeding,10018771.0,Gingival bleeding,10018276.0,Gingival haemorrhages,10055797.0,Dental and gingival conditions,10044018.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-07-28,204.0,211.0,,
0200066003,AE,    34,9.0,13,,Gum bleeding,10018771.0,Gingival bleeding,10018276.0,Gingival haemorrhages,10055797.0,Dental and gingival conditions,10044018.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2012-12-26,2013-03-31,-4.0,92.0,,
0200066003,AE,    34,10.0,32,,Capillary leak syndrome,10007196.0,Capillary leak syndrome,10007196.0,Vascular hypotensive disorders,10057181.0,Decreased and nonspecific blood pressure disorders and shock,10011954.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-04,******,218.0,,AFTER,STUDY END
0200066003,AE,    34,11.0,46,,Common cold,10010106.0,Nasopharyngitis,10028810.0,Upper respiratory tract infections,10046309.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-03,2013-03,64.0,,,
0200066003,AE,    34,12.0,5,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-06,2013-01-27,8.0,29.0,,
0200066003,AE,    34,13.0,16,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-24,2013-03-26,85.0,87.0,,
0200066003,AE,    34,14.0,15,,Vision decreased,10047516.0,Visual acuity reduced,10047531.0,Partial vision loss,10034069.0,Vision disorders,10047518.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-24,******,85.0,,AFTER,STUDY END
0200066003,AE,    34,15.0,48,,Color vision change,10068914.0,Colour blindness acquired,10010051.0,Colour blindness (incl acquired),10005174.0,Vision disorders,10047518.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-14,2013-10-13,106.0,288.0,,
0200066003,AE,    34,16.0,25,,Dry skin,10013786.0,Dry skin,10013786.0,Dermal and epidermal conditions NEC,10012424.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-25,2013-08-04,178.0,218.0,,
0200066003,AE,    34,17.0,35,,Dry skin,10013786.0,Dry skin,10013786.0,Dermal and epidermal conditions NEC,10012424.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,232.0,,AFTER,STUDY END
0200066003,AE,    34,18.0,39,,Edema face,10014222.0,Face oedema,10016029.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-08-13,144.0,227.0,,
0200066003,AE,    34,19.0,40,,Edema face,10014222.0,Face oedema,10016029.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-14,******,228.0,,AFTER,STUDY END
0200066003,AE,    34,20.0,14,,Edema lower limb,10014232.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-03-03,2013-03-31,64.0,92.0,,
0200066003,AE,    34,21.0,21,,Edema lower limb,10014232.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-22,2013-08-13,144.0,227.0,,
0200066003,AE,    34,22.0,22,,Edema lower limb,10014232.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-14,******,228.0,,AFTER,STUDY END
0200066003,AE,    34,23.0,28,,Edema arms,10014214.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-17,******,200.0,,AFTER,STUDY END
0200066003,AE,    34,24.0,29,,Epistaxis,10015090.0,Epistaxis,10015090.0,Nasal disorders NEC,10028731.0,Upper respiratory tract disorders (excl infections),10046304.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-07-28,204.0,211.0,,
0200066003,AE,    34,25.0,12,,Epistaxis,10015090.0,Epistaxis,10015090.0,Nasal disorders NEC,10028731.0,Upper respiratory tract disorders (excl infections),10046304.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-27,2013-03-31,29.0,92.0,,
0200066003,AE,    34,26.0,24,,Lower legs erythematous,10024955.0,Erythema,10015150.0,Erythemas,10015151.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-05,2013-06-13,158.0,166.0,,
0200066003,AE,    34,27.0,26,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-02,2013-08-04,185.0,218.0,,
0200066003,AE,    34,28.0,1,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2012-12-30,2013-03-24,1.0,85.0,,
0200066003,AE,    34,29.0,9,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-27,2013-01-27,29.0,29.0,,
0200066003,AE,    34,30.0,27,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-04,2013-07-04,187.0,187.0,,
0200066003,AE,    34,31.0,45,,Flu-like illness,10016796.0,Influenza like illness,10022004.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-02-24,2013-02,57.0,,,
0200066003,AE,    34,32.0,50,,Hemoglobinemia,10019488.0,Haemoglobinaemia,10018901.0,Haemolyses NEC,10018913.0,Haemolyses and related conditions,10018911.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-07-25,204.0,208.0,,
0200066003,AE,    34,33.0,51,,Hemoglobinemia,10019488.0,Haemoglobinaemia,10018901.0,Haemolyses NEC,10018913.0,Haemolyses and related conditions,10018911.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-25,2013-08-31,239.0,245.0,,
0200066003,AE,    34,34.0,52,,Hemoglobinemia,10019488.0,Haemoglobinaemia,10018901.0,Haemolyses NEC,10018913.0,Haemolyses and related conditions,10018911.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-14,246.0,259.0,,
0200066003,AE,    34,35.0,38,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,2013-09-07,232.0,252.0,,
0200066003,AE,    34,36.0,41,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-08,2013-09-28,253.0,273.0,,
0200066003,AE,    34,37.0,43,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-29,2013-10-05,274.0,280.0,,
0200066003,AE,    34,38.0,44,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-06,2013-12-13,281.0,349.0,,
0200066003,AE,    34,39.0,42,,Left ventricular systolic dysfunction,10069501.0,Left ventricular dysfunction,10049694.0,Myocardial disorders NEC,10028590.0,Myocardial disorders,10028593.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,Y,,3,PTP,Post Treatment Period,POST TREATMENT,2013-10-09,******,284.0,,AFTER,STUDY END
0200066003,AE,    34,40.0,20,,Iron low,10022982.0,Blood iron decreased,10005619.0,Mineral and electrolyte analyses,10027637.0,"Water, electrolyte and mineral investigations",10047843.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-02-04,******,37.0,,AFTER,STUDY END
0200066003,AE,    34,41.0,47,,Muscle pain,10028322.0,Myalgia,10028411.0,Muscle pains,10028323.0,Muscle disorders,10028302.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-06,2013-04,98.0,,,
0200066003,AE,    34,42.0,3,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-06,2013-04-07,8.0,99.0,,
0200066003,AE,    34,43.0,33,,Palpitations,10033557.0,Palpitations,10033557.0,Cardiac signs and symptoms NEC,10007609.0,Cardiac disorder signs and symptoms,10007539.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,232.0,,AFTER,STUDY END
0200066003,AE,    34,44.0,23,,Localized rash,10062705.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-05,2013-06-13,158.0,166.0,,
0200066003,AE,    34,45.0,34,,Taste alteration,10043125.0,Dysgeusia,10013911.0,Sensory abnormalities NEC,10040021.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-18,******,232.0,,AFTER,STUDY END
0200066003,AE,    34,46.0,8,,Taste disturbance,10043132.0,Dysgeusia,10013911.0,Sensory abnormalities NEC,10040021.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-27,2013-04-07,29.0,99.0,,
0200066003,AE,    34,47.0,49,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-16,2013-07-21,199.0,204.0,,
0200066003,AE,    34,48.0,53,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-25,2013-09-08,239.0,253.0,,
0200066003,AE,    34,49.0,54,,Thrombocytopenia,10043554.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-29,2013-10-23,274.0,298.0,,
0200066003,AE,    34,50.0,18,,Urinary infection,10046544.0,Urinary tract infection,10046571.0,Urinary tract infections,10046577.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-21,2013-05-07,113.0,129.0,,
0200066003,AE,    34,51.0,7,,Vertigo,10047340.0,Vertigo,10047340.0,Inner ear signs and symptoms,10022398.0,Inner ear and VIIIth cranial nerve disorders,10022396.0,Ear and labyrinth disorders,10013993.0,Ear and labyrinth disorders,10013993.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-22,2013-01-23,24.0,25.0,,
0200066003,AE,    34,52.0,6,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-20,2013-01-21,22.0,23.0,,
0200066003,AE,    34,53.0,4,,Weight loss,10047900.0,Weight decreased,10047895.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-01-06,2013-04-07,8.0,99.0,,
0200066003,AE,    35,1.0,1,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-12,******,1.0,,AFTER,STUDY END
0200066003,AE,    35,2.0,5,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-10,2013-07-17,29.0,36.0,,
0200066003,AE,    35,3.0,4,,Jaundice,10023126.0,Jaundice,10023126.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,NONE,RELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,Y,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-07-17,******,36.0,,AFTER,STUDY END
0200066003,AE,    35,4.0,11,,Urinary tract infection,10046571.0,Urinary tract infection,10046571.0,Urinary tract infections,10046577.0,Infections - pathogen unspecified,10021879.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-13,******,32.0,,AFTER,STUDY END
0200066003,AE,    35,5.0,8,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-28,2013-07-10,17.0,29.0,,
0200066003,AE,    35,6.0,7,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DRUG INTERRUPTED,NONE,RELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-11,2013-07-24,30.0,43.0,,
0200066003,AE,    35,7.0,14,,Weakness,10047862.0,Asthenia,10003549.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG WITHDRAWN,NONE,RELATED,NONE,FATAL,,,Y,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-11,2013-07-24,30.0,43.0,,
0200066003,AE,    36,1.0,2,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-11-07,******,120.0,,AFTER,STUDY END
0200066003,AE,    36,2.0,1,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-17,2013-10-24,99.0,106.0,,
0200066003,AE,    36,3.0,4,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DOSE NOT CHANGED,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,,,,2013-12-11,2013-12-11,154.0,154.0,,
0200066003,AE,    36,4.0,3,,Obstipation,10029932.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,UNRELATED,CONCOMITANT MEDICATION,RECOVERED/RESOLVED,,,,,,,Y,1,MSCRN,Monotherapy Screening,MONOTHERAPY SCREENING,2013-11-21,2013-12-11,134.0,154.0,,
0200066003,AE,    37,1.0,8,,Alopecia,10001760.0,Alopecia,10001760.0,Alopecias,10001769.0,Skin appendage conditions,10040798.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-24,******,183.0,,AFTER,STUDY END
0200066003,AE,    37,2.0,44,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-04-01,******,281.0,,AFTER,STUDY END
0200066003,AE,    37,3.0,45,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2014-05-20,2014-05-20,330.0,330.0,,
0200066003,AE,    37,4.0,36,,Hyperkalemia,10020647.0,Hyperkalaemia,10020646.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,Y,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,Y,,4,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-21,2014-01-28,211.0,218.0,,
0200066003,AE,    37,5.0,37,,Hyperkalemia,10020647.0,Hyperkalaemia,10020646.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-28,2014-02-03,218.0,224.0,,
0200066003,AE,    37,6.0,3,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-30,2013-08-06,36.0,43.0,,
0200066003,AE,    37,7.0,9,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-03,2013-12-10,162.0,169.0,,
0200066003,AE,    37,8.0,13,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-14,2014-01-21,204.0,211.0,,
0200066003,AE,    37,9.0,41,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-03-25,2014-03-31,274.0,280.0,,
0200066003,AE,    37,10.0,42,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,MULTIPLE,,RELATED,NONE,,,,,,,Y,Y,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-04-01,2014-04-07,281.0,287.0,,
0200066003,AE,    37,11.0,43,,Mucositis oral,10028130.0,Stomatitis,10042128.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-04-08,2014-04-15,288.0,295.0,,
0200066003,AE,    37,12.0,14,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-27,2013-06-27,3.0,3.0,,
0200066003,AE,    37,13.0,15,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-06-30,2013-06-30,6.0,6.0,,
0200066003,AE,    37,14.0,16,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-02,2013-07-02,8.0,8.0,,
0200066003,AE,    37,15.0,17,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-05,2013-07-05,11.0,11.0,,
0200066003,AE,    37,16.0,18,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-12,2013-07-12,18.0,18.0,,
0200066003,AE,    37,17.0,19,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-14,2013-07-14,20.0,20.0,,
0200066003,AE,    37,18.0,20,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-19,2013-07-19,25.0,25.0,,
0200066003,AE,    37,19.0,21,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-21,2013-07-21,27.0,27.0,,
0200066003,AE,    37,20.0,22,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-25,2013-07-25,31.0,31.0,,
0200066003,AE,    37,21.0,23,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-28,2013-07-28,34.0,34.0,,
0200066003,AE,    37,22.0,24,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-02,2013-08-02,39.0,39.0,,
0200066003,AE,    37,23.0,25,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-04,2013-08-04,41.0,41.0,,
0200066003,AE,    37,24.0,26,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-08,45.0,45.0,,
0200066003,AE,    37,25.0,27,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-11,2013-08-11,48.0,48.0,,
0200066003,AE,    37,26.0,28,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-13,2013-08-13,50.0,50.0,,
0200066003,AE,    37,27.0,29,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-16,2013-08-16,53.0,53.0,,
0200066003,AE,    37,28.0,30,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-23,2013-08-23,60.0,60.0,,
0200066003,AE,    37,29.0,31,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-25,2013-08-25,62.0,62.0,,
0200066003,AE,    37,30.0,32,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-29,2013-08-29,66.0,66.0,,
0200066003,AE,    37,31.0,33,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-01,69.0,69.0,,
0200066003,AE,    37,32.0,34,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-06,2013-09-06,74.0,74.0,,
0200066003,AE,    37,33.0,35,,Overdose,10033295.0,Overdose,10033295.0,Overdoses NEC,10076292.0,Product use issues,10076290.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,Y,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-08,2013-09-08,76.0,76.0,,
0200066003,AE,    37,34.0,7,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,NOT APPLICABLE,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-02,2013-10-22,100.0,120.0,,
0200066003,AE,    37,35.0,38,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,Y,MULTIPLE,,RELATED,NONE,,,,,,,Y,Y,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-03-25,2014-03-31,274.0,280.0,,
0200066003,AE,    37,36.0,39,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,,RELATED,NONE,,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-04-01,2014-04-07,281.0,287.0,,
0200066003,AE,    37,37.0,40,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-04-08,2014-04-15,288.0,295.0,,
0200066003,AE,    38,1.0,11,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-02-17,******,-6.0,,AFTER,STUDY END
0200066003,AE,    38,2.0,4,,Haematemesis,10018830.0,Haematemesis,10018830.0,Non-site specific gastrointestinal haemorrhages,10017958.0,Gastrointestinal haemorrhages NEC,10017959.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2013-03-02,2013-03-02,8.0,8.0,,
0200066003,AE,    38,3.0,8,,Hemorrhagic anemia,10052294.0,Haemorrhagic anaemia,10052293.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-03-02,******,8.0,,AFTER,STUDY END
0200066003,AE,    38,4.0,10,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,3,SCRN,Screening,SCREENING,2013-02-17,2013-02-23,-6.0,1.0,,
0200066003,AE,    38,5.0,9,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-02-23,2013-03-02,1.0,8.0,,
0200066003,AE,    38,6.0,7,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2013-03-02,2013-03-02,8.0,8.0,,
0200066003,AE,    38,7.0,2,,Hyperglycemia,10020639.0,Hyperglycaemia,10020635.0,Hyperglycaemic conditions NEC,10020638.0,Glucose metabolism disorders (incl diabetes mellitus),10018424.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,PTP,Post Treatment Period,POST TREATMENT,2013-03-03,******,9.0,,AFTER,STUDY END
0200066003,AE,    38,8.0,12,,Hyponatremia,10021038.0,Hyponatraemia,10021036.0,Sodium imbalance,10041273.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-02-17,2013-03-02,-6.0,8.0,,
0200066003,AE,    38,9.0,14,,Astigmatism,10003569.0,Astigmatism,10003569.0,Refractive and accommodative disorders,10038267.0,Vision disorders,10047518.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-02-22,******,-1.0,,AFTER,STUDY END
0200066003,AE,    38,10.0,13,,Corneal stromal oedema,10054780.0,Corneal oedema,10011033.0,"Corneal infections, oedemas and inflammations",10011021.0,"Ocular infections, irritations and inflammations",10021877.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DOSE NOT CHANGED,NONE,UNRELATED,PAST INTERCURRENT DISEASE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-02-22,******,-1.0,,AFTER,STUDY END
0200066003,AE,    38,11.0,5,,Liver failure,10024678.0,Hepatic failure,10019663.0,Hepatic failure and associated disorders,10019664.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2013-03-17,2013-03-23,23.0,29.0,,
0200066003,AE,    38,12.0,3,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2013-03-03,2013-03-06,9.0,12.0,,
0200066003,AE,    38,13.0,6,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,PTP,Post Treatment Period,POST TREATMENT,2013-03-22,******,28.0,,AFTER,STUDY END
0200066003,AE,    38,14.0,1,,Upper gastrointestinal haemorrhage,10046274.0,Upper gastrointestinal haemorrhage,10046274.0,Non-site specific gastrointestinal haemorrhages,10017958.0,Gastrointestinal haemorrhages NEC,10017959.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,Y,DRUG WITHDRAWN,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2013-03-02,2013-03-08,8.0,14.0,,
0200066003,AE,    39,1.0,50,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2014-06-04,2014-06-11,277.0,284.0,,
0200066003,AE,    39,2.0,1,,Alanine aminotransferase increased,10001551.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-04,1.0,4.0,,
0200066003,AE,    39,3.0,5,,Alanine aminotransferase increased,10001551.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-05,2013-09-09,5.0,9.0,,
0200066003,AE,    39,4.0,6,,Alanine aminotransferase increased,10001551.0,Alanine aminotransferase increased,10001551.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-10,2013-09-16,10.0,16.0,,
0200066003,AE,    39,5.0,47,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,Y,,,Y,3,PTP,Post Treatment Period,POST TREATMENT,2014-06-04,******,277.0,,AFTER,STUDY END
0200066003,AE,    39,6.0,17,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-30,2013-12-15,91.0,106.0,,
0200066003,AE,    39,7.0,27,,Cholangitis,10008604.0,Cholangitis,10008604.0,Bile duct infections and inflammations,10004607.0,Bile duct disorders,10004606.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-29,2014-02-06,151.0,159.0,,
0200066003,AE,    39,8.0,29,,Aphtha,10067589.0,Aphthous stomatitis,10002958.0,Stomatitis and ulceration,10042129.0,Oral soft tissue conditions,10031013.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-01,2014-02-06,154.0,159.0,,
0200066003,AE,    39,9.0,3,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-04,1.0,4.0,,
0200066003,AE,    39,10.0,4,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,MULTIPLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-05,2013-09-15,5.0,15.0,,
0200066003,AE,    39,11.0,10,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-23,2013-09-30,23.0,30.0,,
0200066003,AE,    39,12.0,8,,Blood bilirubin increased,10005364.0,Blood bilirubin increased,10005364.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DRUG INTERRUPTED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-16,2013-09-22,16.0,22.0,,
0200066003,AE,    39,13.0,34,,Intercostal neuralgia,10049949.0,Intercostal neuralgia,10049949.0,Sensory abnormalities NEC,10040021.0,Neurological disorders NEC,10029305.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2013-12-30,121.0,121.0,,
0200066003,AE,    39,14.0,33,,Icterus,10021207.0,Jaundice,10023126.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-30,2013-12-08,91.0,99.0,,
0200066003,AE,    39,15.0,14,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-01,2013-10-01,31.0,31.0,,
0200066003,AE,    39,16.0,25,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-10,2013-10-10,40.0,40.0,,
0200066003,AE,    39,17.0,51,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2014-06-06,2014-06-06,279.0,279.0,,
0200066003,AE,    39,18.0,32,,Epigastric pain,10015026.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-29,2013-11-29,90.0,90.0,,
0200066003,AE,    39,19.0,37,,Epigastric pain,10015026.0,Abdominal pain upper,10000087.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-15,2014-02-27,168.0,180.0,,
0200066003,AE,    39,20.0,18,,Chills,10008531.0,Chills,10008531.0,Feelings and sensations NEC,10068759.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-30,2013-12-15,91.0,106.0,,
0200066003,AE,    39,21.0,11,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-16,2013-09-16,16.0,16.0,,
0200066003,AE,    39,22.0,12,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-24,2013-09-25,24.0,25.0,,
0200066003,AE,    39,23.0,13,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-10-06,30.0,36.0,,
0200066003,AE,    39,24.0,22,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-07,2013-10-09,37.0,39.0,,
0200066003,AE,    39,25.0,26,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-18,2013-10-24,48.0,54.0,,
0200066003,AE,    39,26.0,35,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-30,2014-01-06,121.0,128.0,,
0200066003,AE,    39,27.0,36,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-19,2014-01-27,141.0,149.0,,
0200066003,AE,    39,28.0,42,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-07,2014-03-25,188.0,206.0,,
0200066003,AE,    39,29.0,44,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-13,2014-05-25,255.0,267.0,,
0200066003,AE,    39,30.0,45,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-26,2014-06-09,268.0,282.0,,
0200066003,AE,    39,31.0,49,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,3,PTP,Post Treatment Period,POST TREATMENT,2014-06-10,2014-06-11,283.0,284.0,,
0200066003,AE,    39,32.0,15,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-30,2013-09-30,30.0,30.0,,
0200066003,AE,    39,33.0,24,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-07,2013-10-08,37.0,38.0,,
0200066003,AE,    39,34.0,23,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-28,2013-10-28,58.0,58.0,,
0200066003,AE,    39,35.0,19,,Fever,10016558.0,Pyrexia,10037660.0,Febrile disorders,10016286.0,Body temperature conditions,10005908.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-30,******,91.0,,AFTER,STUDY END
0200066003,AE,    39,36.0,30,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-20,2014-02-12,142.0,165.0,,
0200066003,AE,    39,37.0,40,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-13,2014-03-18,166.0,199.0,,
0200066003,AE,    39,38.0,41,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-19,2014-05-19,200.0,261.0,,
0200066003,AE,    39,39.0,9,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-01,2013-09-15,1.0,15.0,,
0200066003,AE,    39,40.0,46,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-26,******,268.0,,AFTER,STUDY END
0200066003,AE,    39,41.0,20,,Herpes labialis,10019942.0,Oral herpes,10067152.0,Herpes viral infections,10019972.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-04,2013-12-23,95.0,114.0,,
0200066003,AE,    39,42.0,28,,Herpes labialis,10019942.0,Oral herpes,10067152.0,Herpes viral infections,10019972.0,Viral infectious disorders,10047438.0,Infections and infestations,10021881.0,Infections and infestations,10021881.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-01,2014-02-06,154.0,159.0,,
0200066003,AE,    39,43.0,2,,Jaundice extrahepatic obstructive,10023130.0,Jaundice extrahepatic obstructive,10023130.0,Cholestasis and jaundice,10008636.0,Hepatic and hepatobiliary disorders,10019654.0,Hepatobiliary disorders,10019805.0,Hepatobiliary disorders,10019805.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-05,2013-09-11,5.0,11.0,,
0200066003,AE,    39,44.0,31,,Oedema lower limb,10030109.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-09,2013-12-13,100.0,104.0,,
0200066003,AE,    39,45.0,43,,Lumbar pain,10024998.0,Back pain,10003988.0,Musculoskeletal and connective tissue pain and discomfort,10068757.0,Musculoskeletal and connective tissue disorders NEC,10028393.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-12,2014-05-19,254.0,261.0,,
0200066003,AE,    39,46.0,38,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-24,2014-02-27,177.0,180.0,,
0200066003,AE,    39,47.0,48,,Pulmonary embolism,10037377.0,Pulmonary embolism,10037377.0,Pulmonary thrombotic and embolic conditions,10037439.0,Pulmonary vascular disorders,10037454.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,Y,NOT APPLICABLE,NONE,UNRELATED,NONE,FATAL,,,Y,,,,,5,PTP,Post Treatment Period,POST TREATMENT,2014-06-11,2014-06-11,284.0,284.0,,
0200066003,AE,    39,48.0,21,,Infected neoplasm,10058014.0,Infected neoplasm,10058014.0,Oncologic complications and emergencies,10030315.0,Neoplasm related morbidities,10068775.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,Y,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-09,2013-12-19,100.0,110.0,,
0200066003,AE,    39,49.0,39,,White blood cell decreased,10049182.0,White blood cell count decreased,10047942.0,White blood cell analyses,10047938.0,Haematology investigations (incl blood groups),10018851.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-02-24,2014-02-27,177.0,180.0,,
0200066003,AE,    40,1.0,10,,Constipation,10010774.0,Constipation,10010774.0,Gastrointestinal atonic and hypomotility disorders NEC,10017933.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-20,2013-11-20,29.0,29.0,,
0200066003,AE,    40,2.0,3,,Diarrhoea,10012735.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-15,2013-12-16,54.0,55.0,,
0200066003,AE,    40,3.0,5,,Diarrhoea,10012735.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-03,2014-01-07,73.0,77.0,,
0200066003,AE,    40,4.0,6,,Diarrhoea,10012735.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-09,2014-02-26,79.0,127.0,,
0200066003,AE,    40,5.0,7,,Dyspnoea,10013968.0,Dyspnoea,10013968.0,Breathing abnormalities,10006334.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-22,******,92.0,,AFTER,STUDY END
0200066003,AE,    40,6.0,9,,Epiretinal membrane,10064697.0,Macular fibrosis,10071392.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,NOT APPLICABLE,NONE,,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-10-14,******,-9.0,,AFTER,STUDY END
0200066003,AE,    40,7.0,8,,Epiretinal membrane,10064697.0,Macular fibrosis,10071392.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,NOT APPLICABLE,NONE,,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-10-14,******,-9.0,,AFTER,STUDY END
0200066003,AE,    40,8.0,2,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-20,2014-02-26,29.0,127.0,,
0200066003,AE,    40,9.0,11,,Flatulence,10016766.0,Flatulence,10016766.0,"Flatulence, bloating and distension",10016770.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-15,2014-01-29,85.0,99.0,,
0200066003,AE,    40,10.0,12,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-29,2013-12-10,7.0,49.0,,
0200066003,AE,    40,11.0,13,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-11,2013-12-23,50.0,62.0,,
0200066003,AE,    40,12.0,14,,GGT increased,10056910.0,Gamma-glutamyltransferase increased,10017693.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-24,2014-04-25,63.0,185.0,,
0200066003,AE,    40,13.0,4,,Palpitations,10033557.0,Palpitations,10033557.0,Cardiac signs and symptoms NEC,10007609.0,Cardiac disorder signs and symptoms,10007539.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-18,2013-12-18,57.0,57.0,,
0200066003,AE,    40,14.0,1,,Pulmonary embolism,10037377.0,Pulmonary embolism,10037377.0,Pulmonary thrombotic and embolic conditions,10037439.0,Pulmonary vascular disorders,10037454.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,3,SCRN,Screening,SCREENING,2013-10-16,******,-7.0,,AFTER,STUDY END
0200066003,AE,    41,1.0,2,,Tumor pain,10045158.0,Tumour pain,10045171.0,Oncologic complications and emergencies,10030315.0,Neoplasm related morbidities,10068775.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,Y,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,Y,,,Y,3,SCRN,Screening,SCREENING,2013-04-11,2013-04-14,-1.0,3.0,,
0200066003,AE,    41,2.0,15,,Bilateral cataracts,10004558.0,Cataract,10007739.0,Cataract conditions,10007772.0,"Anterior eye structural change, deposit and degeneration",10002693.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,NOT APPLICABLE,NONE,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-04-11,******,-1.0,,AFTER,STUDY END
0200066003,AE,    41,3.0,12,,Serous detachment of the macula,10062968.0,Macular detachment,10075873.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DRUG INTERRUPTED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-07-05,2013-07-18,85.0,98.0,,
0200066003,AE,    41,4.0,5,,Cephalgia,10008013.0,Headache,10019211.0,Headaches NEC,10019233.0,Headaches,10019231.0,Nervous system disorders,10029205.0,Nervous system disorders,10029205.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-18,2013-04-19,7.0,8.0,,
0200066003,AE,    41,5.0,13,,Diarrhea,10012727.0,Diarrhoea,10012735.0,Diarrhoea (excl infective),10012736.0,Gastrointestinal motility and defaecation conditions,10017977.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-04-05,2013-04-10,-7.0,-2.0,,
0200066003,AE,    41,6.0,10,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-26,2013-08-16,15.0,127.0,,
0200066003,AE,    41,7.0,3,,Hypertension,10020772.0,Hypertension,10020772.0,Vascular hypertensive disorders NEC,10020774.0,Vascular hypertensive disorders,10057166.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,Y,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,Y,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-19,2013-04-20,8.0,9.0,,
0200066003,AE,    41,8.0,16,,Hypocalcemia,10020949.0,Hypocalcaemia,10020947.0,Calcium metabolism disorders,10006975.0,"Bone, calcium, magnesium and phosphorus metabolism disorders",10013296.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-12,2013-04-19,1.0,8.0,,
0200066003,AE,    41,9.0,7,,Hypokalaemia,10021015.0,Hypokalaemia,10021015.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-12,2013-04-13,1.0,2.0,,
0200066003,AE,    41,10.0,11,,Oedema legs,10030105.0,Oedema peripheral,10030124.0,Oedema NEC,10030113.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,MULTIPLE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-03,2013-08-16,22.0,127.0,,
0200066003,AE,    41,11.0,19,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,SCRN,Screening,SCREENING,2013-04-11,2013-05-03,-1.0,22.0,,
0200066003,AE,    41,12.0,8,,Visual acuity decreased,10049061.0,Visual acuity reduced,10047531.0,Partial vision loss,10034069.0,Vision disorders,10047518.0,Eye disorders,10015919.0,Eye disorders,10015919.0,N,DRUG INTERRUPTED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-07-05,2013-07-18,85.0,98.0,,
0200066003,AE,    41,13.0,14,,Skin induration,10051837.0,Skin induration,10051837.0,Dermal and epidermal conditions NEC,10012424.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-03,2013-05-10,22.0,29.0,,
0200066003,AE,    41,14.0,6,,Sinus tachycardia,10040752.0,Sinus tachycardia,10040752.0,Supraventricular arrhythmias,10042600.0,Cardiac arrhythmias,10007521.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-19,2013-04-20,8.0,9.0,,
0200066003,AE,    41,15.0,17,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-07-04,2013-08-01,84.0,112.0,,
0200066003,AE,    41,16.0,9,,Transaminases increased,10054889.0,Transaminases increased,10054889.0,Liver function analyses,10024689.0,Hepatobiliary investigations,10019809.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-26,2013-05-10,15.0,29.0,,
0200066003,AE,    41,17.0,4,,Vomiting,10047700.0,Vomiting,10047700.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-04-18,2013-04-18,7.0,7.0,,
0200066003,AE,    41,18.0,1,,Weight gain,10047896.0,Weight increased,10047899.0,Physical examination procedures and organ system status,10071941.0,Physical examination and organ system status topics,10071940.0,Investigations,10022891.0,Investigations,10022891.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-10,2013-07-19,29.0,99.0,,
0200066003,AE,    42,1.0,12,,Abdominal pain,10000081.0,Abdominal pain,10000081.0,Gastrointestinal and abdominal pains (excl oral and throat),10017926.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-26,2014-01-08,113.0,126.0,,
0200066003,AE,    42,2.0,1,,Anemia of chronic disease,10054310.0,Anaemia of chronic disease,10002073.0,Anaemias due to chronic disorders,10052827.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-19,2013-10-23,15.0,49.0,,
0200066003,AE,    42,3.0,18,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-11-14,2013-11-27,71.0,84.0,,
0200066003,AE,    42,4.0,3,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,,,,,,Y,,Y,4,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-11-28,2013-12-01,85.0,88.0,,
0200066003,AE,    42,5.0,6,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-02,2013-12-25,89.0,112.0,,
0200066003,AE,    42,6.0,8,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,,,,,Y,Y,,Y,4,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-26,2013-12-27,113.0,114.0,,
0200066003,AE,    42,7.0,19,,Anemia,10002272.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DRUG INTERRUPTED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,MPTP,Monotherapy Post Treatment Period,MONOTHERAPY POST TREATMENT,2013-12-27,******,114.0,,AFTER,STUDY END
0200066003,AE,    42,8.0,2,,Anemia of chronic disease,10054310.0,Anaemia of chronic disease,10002073.0,Anaemias due to chronic disorders,10052827.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-24,2013-11-14,50.0,71.0,,
0200066003,AE,    42,9.0,9,,Ascites,10003445.0,Ascites,10003445.0,Peritoneal and retroperitoneal disorders,10034653.0,Peritoneal and retroperitoneal conditions,10034652.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,NOT APPLICABLE,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-26,2014-01-08,113.0,126.0,,
0200066003,AE,    42,10.0,10,,Circulatory collapse,10009192.0,Circulatory collapse,10009192.0,Circulatory collapse and shock,10009193.0,Decreased and nonspecific blood pressure disorders and shock,10011954.0,Vascular disorders,10047065.0,Vascular disorders,10047065.0,N,NOT APPLICABLE,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-12-26,2013-12-26,113.0,113.0,,
0200066003,AE,    42,11.0,17,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,NOT APPLICABLE,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,FU,Follow-up Period,FOLLOW-UP,2014-01-12,2014-01-12,130.0,130.0,,
0200066003,AE,    42,12.0,13,,CPK increased,10011268.0,Blood creatine phosphokinase increased,10005470.0,Skeletal and cardiac muscle analyses,10040768.0,Enzyme investigations NEC,10014938.0,Investigations,10022891.0,Investigations,10022891.0,Y,NOT APPLICABLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,4,MPTP,Monotherapy Post Treatment Period,MONOTHERAPY POST TREATMENT,2013-12-27,2013-12-30,114.0,117.0,,
0200066003,AE,    42,13.0,7,,Hypoalbuminemia,10020943.0,Hypoalbuminaemia,10020942.0,Protein metabolism disorders NEC,10037009.0,Protein and amino acid metabolism disorders NEC,10037008.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,,Y,2,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-11-28,******,85.0,,AFTER,STUDY END
0200066003,AE,    42,14.0,15,,Leukemoid reaction,10024373.0,Leukaemoid reaction,10024328.0,Leukocytoses NEC,10024379.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,Y,DRUG INTERRUPTED,NONE,UNRELATED,DISEASE UNDER STUDY,NOT RECOVERED/NOT RESOLVED,,,,,,Y,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-03,******,29.0,,AFTER,STUDY END
0200066003,AE,    42,15.0,4,,Macular oedema,10025415.0,Macular oedema,10025415.0,"Retinal, choroid and vitreous infections and inflammations",10038909.0,"Ocular infections, irritations and inflammations",10021877.0,Eye disorders,10015919.0,Eye disorders,10015919.0,Y,MULTIPLE,,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,Y,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2013-11-16,2013-11-21,73.0,78.0,,
0200066003,AE,    43,1.0,4,,Anorexia,10002646.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-16,2014-09-26,3.0,348.0,,
0200066003,AE,    43,2.0,13,,Cough,10011224.0,Cough,10011224.0,Coughing and associated symptoms,10011233.0,Respiratory disorders NEC,10038716.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,"Respiratory, thoracic and mediastinal disorders",10038738.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-07,2014-09-26,86.0,348.0,,
0200066003,AE,    43,3.0,21,,Detachment retinal,10012542.0,Retinal detachment,10038848.0,"Retinal structural change, deposit and degeneration",10038896.0,"Ocular structural change, deposit and degeneration NEC",10042261.0,Eye disorders,10015919.0,Eye disorders,10015919.0,Y,MULTIPLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-07-22,2014-08-05,282.0,296.0,,
0200066003,AE,    43,4.0,3,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-16,2014-09-26,3.0,348.0,,
0200066003,AE,    43,5.0,7,,Hyperkalemia,10020647.0,Hyperkalaemia,10020646.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-17,2013-11-25,35.0,43.0,,
0200066003,AE,    43,6.0,8,,Hyperkalemia,10020647.0,Hyperkalaemia,10020646.0,Potassium imbalance,10036451.0,Electrolyte and fluid balance conditions,10014412.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-25,2013-12-01,43.0,49.0,,
0200066003,AE,    43,7.0,10,,Insomnia,10022437.0,Insomnia,10022437.0,Disturbances in initiating and maintaining sleep,10013510.0,Sleep disorders and disturbances,10040991.0,Psychiatric disorders,10037175.0,Psychiatric disorders,10037175.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-11,2014-09-26,59.0,348.0,,
0200066003,AE,    43,8.0,2,,Leucopenia,10024283.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-20,2013-11-17,7.0,35.0,,
0200066003,AE,    43,9.0,12,,Leukopenia,10024384.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-15,2014-01-05,63.0,84.0,,
0200066003,AE,    43,10.0,16,,Leukopenia,10024384.0,Leukopenia,10024384.0,Leukopenias NEC,10024385.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-13,2014-01-19,92.0,98.0,,
0200066003,AE,    43,11.0,20,,Macular oedema,10025415.0,Macular oedema,10025415.0,"Retinal, choroid and vitreous infections and inflammations",10038909.0,"Ocular infections, irritations and inflammations",10021877.0,Eye disorders,10015919.0,Eye disorders,10015919.0,Y,MULTIPLE,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,Y,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-07-22,2014-08-05,282.0,296.0,,
0200066003,AE,    43,12.0,18,,Myocardial infarction,10028596.0,Myocardial infarction,10028596.0,Ischaemic coronary artery disorders,10011085.0,Coronary artery disorders,10011082.0,Cardiac disorders,10007541.0,Cardiac disorders,10007541.0,Y,DOSE NOT CHANGED,,UNRELATED,PAST INTERCURRENT DISEASE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,Y,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-05-22,2014-06-24,221.0,254.0,,
0200066003,AE,    43,13.0,1,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-10-20,2013-11-04,7.0,22.0,,
0200066003,AE,    43,14.0,5,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-04,2013-11-10,22.0,28.0,,
0200066003,AE,    43,15.0,6,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-11-10,2013-11-17,28.0,35.0,,
0200066003,AE,    43,16.0,11,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-15,2014-01-05,63.0,84.0,,
0200066003,AE,    43,17.0,15,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-13,2014-01-19,92.0,98.0,,
0200066003,AE,    43,18.0,17,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-03-16,2014-03-23,154.0,161.0,,
0200066003,AE,    43,19.0,9,,Painful joints,10033511.0,Arthralgia,10003239.0,Joint related signs and symptoms,10023226.0,Joint disorders,10023213.0,Musculoskeletal and connective tissue disorders,10028395.0,Musculoskeletal and connective tissue disorders,10028395.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-12-10,2014-09-26,58.0,348.0,,
0200066003,AE,    43,20.0,14,,Postoperative hernia,10050356.0,Postoperative hernia,10050356.0,Non-site specific procedural complications,10029559.0,Procedural related injuries and complications NEC,10069888.0,"Injury, poisoning and procedural complications",10022117.0,"Injury, poisoning and procedural complications",10022117.0,N,DOSE NOT CHANGED,,UNRELATED,OTHER,RECOVERED/RESOLVED,,,,,,,Y,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2014-01-09,2014-09-26,88.0,348.0,,
0200066003,AE,    43,21.0,19,,Disease progression,10061818.0,Disease progression,10061818.0,General signs and symptoms NEC,10018072.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,Y,DRUG WITHDRAWN,LED TO STUDY TERMINATION,UNRELATED,DISEASE UNDER STUDY,FATAL,,,Y,,,,,5,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-09-16,2014-09-26,338.0,348.0,,
0200066003,AE,    43,22.0,22,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,MULTIPLE,NONE,RELATED,NONE,RECOVERED/RESOLVED WITH SEQUELAE,,,,,,,,3,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-08-25,2014-09-07,316.0,329.0,,
0200066003,AE,    43,23.0,23,,Skin rash,10040913.0,Rash,10037844.0,"Rashes, eruptions and exanthems NEC",10052566.0,Epidermal and dermal conditions,10014982.0,Skin and subcutaneous tissue disorders,10040785.0,Skin and subcutaneous tissue disorders,10040785.0,N,DOSE NOT CHANGED,NONE,RELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,MONOTHER,Pimasertib Monotherapy,MONOTHERAPY TREATMENT,2014-09-08,2014-09-26,330.0,348.0,,
0200066003,AE,    44,1.0,1,,Cancer pain,10058019.0,Cancer pain,10058019.0,Oncologic complications and emergencies,10030315.0,Neoplasm related morbidities,10068775.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",10029104.0,N,DOSE NOT CHANGED,,UNRELATED,DISEASE UNDER STUDY,,,,,,,,Y,3,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-09,2013-08-01,1.0,85.0,,
0200066003,AE,    44,2.0,3,,Fatigue,10016256.0,Fatigue,10016256.0,Asthenic conditions,10003550.0,General system disorders NEC,10018073.0,General disorders and administration site conditions,10018065.0,General disorders and administration site conditions,10018065.0,N,DOSE NOT CHANGED,NONE,UNRELATED,OTHER,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-23,******,15.0,,AFTER,STUDY END
0200066003,AE,    44,3.0,15,,Appetite lost,10003028.0,Decreased appetite,10061428.0,Appetite disorders,10003022.0,Appetite and general nutritional disorders,10003018.0,Metabolism and nutrition disorders,10027433.0,Metabolism and nutrition disorders,10027433.0,N,DOSE NOT CHANGED,NONE,UNRELATED,DISEASE UNDER STUDY,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-13,2013-08-28,97.0,112.0,,
0200066003,AE,    44,4.0,16,,Nausea,10028813.0,Nausea,10028813.0,Nausea and vomiting symptoms,10028817.0,Gastrointestinal signs and symptoms,10018012.0,Gastrointestinal disorders,10017947.0,Gastrointestinal disorders,10017947.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-15,2013-08-28,99.0,112.0,,
0200066003,AE,    44,5.0,10,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-14,92.0,98.0,,
0200066003,AE,    44,6.0,11,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-15,2013-08-21,99.0,105.0,,
0200066003,AE,    44,7.0,12,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-22,2013-08-29,106.0,113.0,,
0200066003,AE,    44,8.0,6,,Neutropenia,10029354.0,Neutropenia,10029354.0,Neutropenias,10029355.0,White blood cell disorders,10047954.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-05,2013-09-26,120.0,141.0,,
0200066003,AE,    44,9.0,18,,Anemia post chemotherapy,10064469.0,Anaemia,10002034.0,Anaemias NEC,10002067.0,Anaemias nonhaemolytic and marrow depression,10002086.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-05-30,2013-08-08,22.0,92.0,,
0200066003,AE,    44,10.0,2,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-07-18,2013-07-26,71.0,79.0,,
0200066003,AE,    44,11.0,7,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-08,2013-08-14,92.0,98.0,,
0200066003,AE,    44,12.0,8,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-15,2013-08-21,99.0,105.0,,
0200066003,AE,    44,13.0,9,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,RECOVERED/RESOLVED,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-08-22,2013-08-29,106.0,113.0,,
0200066003,AE,    44,14.0,4,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,1,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-05,2013-09-11,120.0,126.0,,
0200066003,AE,    44,15.0,5,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,DOSE NOT CHANGED,NONE,UNRELATED,NONE,,,,,,,,,2,TRT_PLA,Gemcitabine and Placebo,TREATMENT,2013-09-12,2013-09-25,127.0,140.0,,
0200066003,AE,    44,16.0,13,,Thrombopenia,10043569.0,Thrombocytopenia,10043554.0,Thrombocytopenias,10043555.0,Platelet disorders,10035534.0,Blood and lymphatic system disorders,10005329.0,Blood and lymphatic system disorders,10005329.0,N,NOT APPLICABLE,NONE,UNRELATED,NONE,NOT RECOVERED/NOT RESOLVED,,,,,,,,1,PTP,Post Treatment Period,POST TREATMENT,2013-09-26,******,141.0,,AFTER,STUDY END
